Introduction {#s1}
============

The cranial placodes give rise to many sense organs of the vertebrate head (including nose, ear and lateral line) and contribute to the anterior pituitary and sensory ganglia of the cranial nerves. Together with the neural crest, which also contributes to cranial ganglia as well as the head skeleton, they originated as an evolutionary novelty in stem vertebrates, on the adoption of a more active and exploratory life style ([@bib72]; [@bib91]). Defects in placode development underlie many congenital diseases of sensory organs and the endocrine system ([@bib78]; [@bib23]; [@bib106]), however, despite this central importance of placodes in the evolution and development of the vertebrate head, they have been much less well studied than the neural crest, and little is known about the gene regulatory networks (GRNs) driving early placode development.

Fate mapping studies have shown that all cranial placodes develop from a common precursor region, the pre-placodal ectoderm (PPE) ([@bib95]; [@bib10]; [@bib105]; [@bib80]). In neural plate stage embryos, the PPE is located as a horseshoe-shaped domain around the anterior neural plate (and abutting the cranial neural crest laterally) which subsequently breaks up into individual placodes ([@bib90]; [@bib34]; [@bib83]). Molecularly, the PPE is characterised by the expression of *Six1* and *Eya1*, which also continues in most placodes derived from the PPE ([@bib86]). Whereas *Six1* encodes a transcription factor, *Eya1* encodes a transcriptional co-activator that also has phosphatase activity ([@bib51]; [@bib98]), and Six1 and Eya1 have been shown to form a protein complex and synergistically activate transcription ([@bib73]; [@bib57]). However, both Six1 and Eya1 also interact with other protein interaction partners; Six1, for example, has been shown to act as a transcriptional repressor after binding to the co-repressor Groucho ([@bib14]) whereas Eya1 is known to form protein complexes with other binding partners including the transcription factor Sox2 ([@bib2]; [@bib98]).

Loss of Six1 or Eya1 function in mouse, zebrafish, chick or *Xenopus* embryos leads to a similar spectrum of PPE and placodal defects, with altered expression of other PPE genes, decreased proliferation and increased apoptosis in many placodes, compromised morphogenetic movements (invagination or cell delamination) and a decreased production of sensory cells and neurons ([@bib107]; [@bib52]; [@bib110]; [@bib14]; [@bib112]; [@bib50]; [@bib87]; [@bib18]; [@bib2], [@bib3]). In human patients, mutations in both Six1 and Eya1 lead to branchio-oto-renal (BOR) and branchio-otic (BO) syndromes with congenital hearing loss ([@bib48]). These findings suggest that these proteins are core regulators of placode development and promote multiple aspects of placode development synergistically, although Eya1-independent roles of Six1 have also been reported ([@bib14]; [@bib13]). Specifically, Six1 and Eya1 have been shown to play central roles, during multiple steps, in the development of sensory cells (e.g. hair cells in the inner ear) as well as sensory neurons, and promote both the proliferation of sensory/neuronal progenitors as well as sensory and neuronal differentiation in a dosage dependent fashion ([@bib112]; [@bib87]; [@bib111]; [@bib3], [@bib2]). Recently Atoh1, an essential determination gene for hair cell development, has been shown to be directly transcriptionally activated by Six1/Eya1 binding to its enhancer ([@bib2]). Moreover, the neuronal progenitor genes *Sox2* and *Sox3* have been shown to be up-regulated by Six1 and Eya1 in the absence of protein synthesis, suggesting that they are also direct target genes ([@bib87]). Several other direct target genes of Six1 have been identified ([@bib51]; [@bib106]), but no specific screen for direct target genes of Six1 and Eya1 in the PPE and the developing placodes has yet been conducted.

Here, using RNA-Seq in *Xenopus laevis*, we present the first comprehensive screen for presumptive direct target genes of Six1 and Eya1 in the developing placodes in any vertebrate. Hormone-inducible constructs of Six1 and Eya1 (fused with the human glucocorticoid receptor \[GR\]) were overexpressed, either alone or in combination, in *Xenopus* embryos. We then explanted the PPE at neural fold stages and activated nuclear translocation of Six1 or Eya1 in these explants by the addition of dexamethasone (DEX) after blocking protein synthesis by cycloheximide (CHX). This approach has previously been shown to reliably activate direct targets of GR-fusion constructs only in the presence of DEX ([@bib49]; [@bib92]). We then analysed the transcriptome of placodal explants by RNA-Seq and compared this to control explants which were not hormone induced, in order to specifically survey target genes directly activated or repressed by Six1 or Eya1 in the PPE and developing placodes. Using this method, we were able to identify a large number of novel target genes with potentially important roles for cranial placode development. We were further able to show in loss of function studies that several target genes encoding known regulators of progenitor fates (e.g. *Sox2, Hes8*) and neuronal/sensory differentiation (e.g. *Ngn1, Atoh1, Pou4f1.2, Gfi1a*) required both Six1 and Eya1 for their expression in the developing placodes. Our findings provide pioneering insights into the GRNs regulating placode development downstream of Six1 and Eya1, and suggest exciting new avenues of research for understanding placode development and disease.

Results {#s2}
=======

The pre-placodal transcriptome {#s2-1}
------------------------------

RNA was extracted from explants cut from the PPE of un-injected embryos and characterised using RNA-Seq to provide a complete transcriptome of the PPE. After removing genes expressed at low levels (FPKM \< 1) and annotation against a *Xenopus* mRNA database (see Materials and methods), we assembled a transcriptome comprising 15,794 transcripts, and the top 1000 expressed genes are shown in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Gene Set Enrichment Analysis (GSEA) on these genes revealed that RNA processing/splicing was very highly enriched in the PPE transcriptome (enrichment score \[E\]: 43), suggesting that RNA-binding proteins and mRNA splicing mechanisms may play an important role in placodal development as has also been reported for the neural crest ([@bib93]). Translation elongation and ribosomal proteins were also highly enriched (E: 32), perhaps reflecting the high rate of protein turnover in the rapidly changing PPE ([@bib64]).

Identification of direct targets of Six1 and Eya1 in PPE {#s2-2}
--------------------------------------------------------

To identify presumptive direct targets of Six1 and Eya1, Six1-GR and Eya1-GR fusion proteins were overexpressed either alone or together in the PPE. In combination with a protein synthesis inhibitor (CHX), nuclear translocation of Six1 and Eya1 was induced by adding DEX for 2.5 hr, and gene expression was analysed using RNA-Seq ([Figure 1](#fig1){ref-type="fig"}). Presumptive direct targets of Six1 and Eya1 were determined by comparing Six1-GR-, Eya1-GR- or Six1-GR+Eya1-GR-injected embryos treated with CHX alone (as controls) against CHX+DEX-treated samples. Resultant data sets from such [i]{.ul}ndividual treatment groups (each with two biological replicates) are henceforth referred to as Six1~i~, Eya1~i~ and Six1+Eya1~i~. In this paradigm, the expression of target genes for which either Six1 or Eya1 concentrations are limiting in the PPE should be affected in Six1~i~ and Eya1~i~ treatment groups, respectively (and potentially also in Six1+Eya1~i~), while the expression of target genes limited by both Eya1 and Six1 concentrations in the PPE should be modulated only in the Six1+Eya1~i~ treatment group.10.7554/eLife.17666.003Figure 1.Experimental pipeline and overview of bioinformatic analysis.(**A**) Both blastomeres of two-cell stage embryos were injected with Six1-GR, Eya1-GR or Six1-GR+Eya1-GR and explants were cut from pre-placodal ectoderm. Explants were incubated in CHX for 30 min before being split into two groups; 50% were kept in CHX for 2.5 hr and 50% were transferred to CHX+DEX for 2.5 hr. RNA was extracted from both treatment groups and submitted to RNA-Sequencing. (**B**) On average, 80 million reads were generated in sequencing for each treatment group, and 65 million quality-trimmed reads were successfully mapped to the *Xenopus* genome. An average of 49,000 transcript models were assembled, of which 80% (39,000) were successfully annotated against a *Xenopus* mRNA database. Annotated transcript models were then filtered to condense duplicate annotations into 15,794 uniquely annotated transcript models, and differential expression analysis was then performed using CHX treated explants as a control for those treated with CHX+DEX.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.003](10.7554/eLife.17666.003)

Using this approach, we identified 365 genes up-regulated at least twofold that satisfied all criteria for differential expression (log~2~ fold change \[FC\] ≥ 1; FPKM ≥ 1; FC \< 0.5 in un-injected control) in Six1~i~, 508 in Eya1~i~ and 836 in Six1+Eya1~i~, treatment groups, while 292 genes were down-regulated in Six1~i~, 218 in Eya1~i~ and 490 in Six1+Eya1~i~ treatment groups ([Figure 2A and B](#fig2){ref-type="fig"}; [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). As an initial means of estimating data quality, we searched for targets of Six1 established in previous studies (*Atoh1* ([@bib2]); *Slc12a2* ([@bib6]); *CyclinA1* ([@bib20]); *CyclinD1* ([@bib57]); *c-Myc* ([@bib56]); *Ezrin* ([@bib109]); *Gdnf* ([@bib56]); *Sox3* ([@bib87]); *Sox2* ([@bib87]); *Sall1* ([@bib16]); and *MyoD1* ([@bib58])) in the Six1~i~ and Six1+Eya1~i~ data sets. With the exception of *c-Myc,* all genes were present in the transcriptome, and most were found in either Six1~i~ (*CyclinD1 \[ccndx*\] FC: 7.48; *Slc12a2*, FC: -2.75; *CyclinA1*, FC: -3.68; *Sox2*, FC: 1.2; *MyoD, FC: 3.4)* or Six1+Eya1~i~ (*Sox3,* FC: 0.9; *Atoh1*, FC: 1.4; *Sall1*, FC: 0.99) data sets, confirming the utility of our approach in identifying direct targets. Moreover, *Atoh1, Sox2* and *MyoD1* were found both in our Six1+Eya1~i~ and Eya1~i~ datasets as expected based on the known coregulation of these Six1 target genes by Eya1 ([@bib2]; [@bib33]; [@bib87]). We suggest that overexpression of Eya1 alone may upregulate such genes in those parts of the ectoderm where *Six1* is already expressed at high levels but *Eya1* at relatively low levels in vivo.10.7554/eLife.17666.004Figure 2.Differentially expressed genes after overexpression of *Six1* and *Eya1* in the PPE.Plots **A** and **B** show number of genes differentially regulated after overexpression of *Six1* alone (Six1~i~; yellow), *Eya1* alone (Eya1~i~; blue) or *Six1* and *Eya1* combined (Six1+Eya1~i~; green). Each Venn diagram shows the number of genes (red) unique for each treatment group or shared between them. (**A**) Number of genes up-regulated and (**B**) down-regulated after injection with *Six1, Eya1* or *Six1+Eya1*. (**C**) The merged analysis resulted in hundreds of significantly differentially expressed genes in the PPE data set. Plot shows log~2~ transformed (FPKM+1) values after overexpression of *Six1 or Eya1* (combination of all treatment groups; Six1+Eya1~m~). Green points represent significantly (q\<0.05) up-regulated genes and red points show significantly down-regulated genes. Plot **D** shows the enrichment of molecular function terms after overexpression of *Six1* or *Eya1* based on significantly differentially expressed genes from the merged data set (Six1+Eya1~m~; [Supplementary file 3,](#SD3-data){ref-type="supplementary-material"} Table 5). The area of the pie represents the total number of functional terms contained in the analysis, with each slice representing the percentage of genes against this total. Molecular functions shown can be broadly divided into five categories: Green slices are related to binding functions (53%); purple/blue represents enzyme activity (30%); pink/red shows transmembrane proteins (13%); orange cytoskeleton (3%) and yellow anti-oxidant (1%).**DOI:** [http://dx.doi.org/10.7554/eLife.17666.004](10.7554/eLife.17666.004)

Six1 and Eya1 co-regulate many but not all PPE target genes {#s2-3}
-----------------------------------------------------------

Comparison between our different treatment groups allows us to distinguish genes likely co-regulated by Six1 and Eya1 from those that are not and, thus, may be regulated by Six1 or Eya1 alone or in conjunction with other protein-binding partners. Since ectodermal expression of *Six1* and *Eya1* is widely overlapping in vivo but not completely congruent, genes co-regulated by Six1 and Eya1 may be differentially expressed not only after coinjection of Six1 and Eya1 (Six1+Eya1~i~ treatment group) but also after injection of Six1 or Eya1 alone (Six1~i~ and Eya1~i~ treatment groups, respectively) because elevation of Six1 or Eya1 levels will produce higher levels of the coregulatory complex in those parts of the ectoderm where the respective protein is expressed at much lower levels than its binding partner. Hence, a subset of target genes with high response thresholds to the Six1-Eya1 coregulatory complex (e.g. due to low affinity binding sites) will respond to overexpression of Six1 or Eya1 alone with differential expression in these parts of the ectoderm while another subset of genes with low response thresholds (e.g. due to high affinity binding sites) will not. The latter subset will, thus, only be differentially expressed after overexpression of both Six1 and Eya1, creating expanded areas of Six1 and Eya1 coexpression in the ectoderm. Notably, the false discovery rate is expected to be lower for the former subset, which is supported by three independent treatment groups (Six1~i~, Eya1~i~ and Six1+Eya1~i~), than in the latter subset, supported only by one (Six1+Eya1~i~).

About half of all genes differentially expressed in the PPE in our various treatment groups show evidence of co-regulation by Six1 and Eya1. This includes 690 (633+57) up-regulated and 444 (440+4) down-regulated genes ([Figure 2A and B](#fig2){ref-type="fig"}). Indeed, the top 10% of transcripts (ranked by FC; post DEX-filtering) up-regulated in Six1~i~, Eya1~i~ or Six+Eya1~i~ treatment groups were each highly enriched for the top 10% of transcripts up-regulated in any of the other experimental treatment groups (p\<0.0001; Fisher's exact test). More genes co-regulated by Six1 and Eya1 were up-regulated than were down-regulated (690/1134 = 60.8% for all co-regulated genes, 57/61 = 93.4% for co-regulated genes identified in each treatment group; [Figure 2A and B](#fig2){ref-type="fig"}), corroborating previous findings that Six1 and Eya1 typically act synergistically to activate transcription ([@bib3], [@bib2]; [@bib14]; [@bib18]; [@bib56]; [@bib82]). However, our identification of a subset of genes synergistically down-regulated by Six1 and Eya1 suggests that Eya1 may not always act as a co-activator of Six1.

In contrast, there is no support for co-regulation for genes that are differentially expressed only in Six1~i~ but not Eya1~i~ treatment groups (and vice versa) even for those genes that are also differentially expressed after Six1+Eya1~i~ treatment. We identified 283 (190+93) genes up-regulated and 270 (233+37) genes down-regulated by Six1 but not Eya1, indicating that these are regulated by Six1 in an Eya1 independent way but possibly dependent on other co-factors. Conversely, we identified 426 (373+53) genes up-regulated and 196 (187+9) genes down-regulated by Eya1 but not Six1 ([Figure 2A,B](#fig2){ref-type="fig"}) suggesting that these are regulated by Eya1 in conjunction with transcription factors other than Six1.

To add statistical power to our analysis, we next merged treatment groups and determined significantly differentially expressed genes (q\<0.05) in these merged groups. We first created a data set Six1+Eya1~m~ in which all replicates that involved overexpression of either Six1 or Eya1 were considered as equivalent (injection of Six1-GR, Eya1-GR or Six1-GR+Eya1-GR; 6 replicates in total). This allowed us to identify genes that are significantly differentially expressed across all treatment groups. We also created a data set Six1~m~, in which all replicates that involved Six1 overexpression were considered as equivalent (injection of Six1-GR or Six1-GR+Eya1-GR; 4 replicates). This allowed us to identify genes with significant differential expression after Six1 upregulation. Similarly, we created data set Eya1~m~ based on all replicates that involved Eya1 overexpression (injection of Eya1-GR or Six1-GR+Eya1-GR; 4 replicates) allowing us to identify genes differentially expressed after Eya1 upregulation. We found 181 significantly (q\<0.05) up-regulated genes in the Six1+Eya1~m~ group, 149 in Six1~m~ and 112 in Eya1~m~ ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}, Tables 1--3). Substantially fewer genes were negatively regulated in these merged groups, with only 14 significantly down-regulated genes found in Six1+Eya1~m~, 11 in Six1~m~ and 13 in Eya1~m~ ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}, Tables 4--6), re-enforcing the notion that together, Six1 and Eya1 act primarily as transcriptional activators ([Figure 2C](#fig2){ref-type="fig"}).

Target genes of Six1 and Eya1 are implicated in sensory neurogenesis {#s2-4}
--------------------------------------------------------------------

Presumptive direct targets that were significantly up-regulated in our merged data set (Six1+Eya1~m~) were analysed using Panther ([@bib65]) to examine the representation of genes grouped by molecular function ([Figure 2D](#fig2){ref-type="fig"}). Transcription factors and protein binding together accounted for the largest fraction of up-regulated genes (53% in total), followed by enzymes (30%) and transporter molecules (13%), suggesting a developmental function of many of the genes up-regulated by either Six1 or Eya1. GSEA was then conducted using DAVID ([@bib40]) on the sets of significantly up- or down-regulated genes in our merged data sets, as well as in various combinations of subsets of differentially expressed genes from our individual treatment groups ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This analysis showed that genes directly up-regulated by Six1, Eya1 or Six1+Eya1 were highly enriched for terms associated with sense organ development, inner-ear development, mechanoreceptor differentiation, eye morphogenesis, neurogenesis and axon guidance consistent with their synergistic role in sensory development ([@bib34]; [@bib90]) and neurogenesis ([@bib62]; [@bib88]). Apart from genes encoding transcription factors involved in sensory development (see below), genes encoding cell cycle regulators (*CyclinD, RGCC*), cell surface receptors and adhesion molecules (e.g. *CXCR7, EDAR, Protocadherin11, Claudin3, Fzd1, Fzd4*,), secreted proteins (e.g. *FGF3, FGF19, Dkk1, Neurotrophin3*) and cytoskeletal regulators (e.g. *RhoV, Espin*) with known or potential roles in placode development were also up-regulated.10.7554/eLife.17666.005Figure 3.Gene set enrichment analysis (GSEA) showing enriched clusters of functional terms for up-regulated genes in different treatment groups.In each case, treatment groups considered are highlighted and outlined in bold in the accompanying Venn diagram. Yellow colouring indicates Six1 treatment; blue shows Eya1 and green Six1+Eya1. Enrichment scores ≥1.5 are reported for individual treatment groups (Ind.) and, where available, ≥0.5 for merged treatment groups (Merg.). (**A**) Up-regulated genes from all treatment groups included in analysis; (**B**) *Six1* overexpression only; (**C**) *Eya1* overexpression only. (**D**) Genes differentially expressed after overexpression of both *Six1* and *Eya1*; (**E**) exclusively after *Six1* overexpression; (**F**) exclusively after *Eya1* overexpression.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.005](10.7554/eLife.17666.005)10.7554/eLife.17666.006Figure 3---figure supplement 1.Gene set enrichment analysis (GSEA) showing enriched clusters of functional terms for down-regulated genes in different treatment groups.In each case, treatment groups considered are highlighted and outlined in bold in the accompanying Venn diagram. Yellow colouring indicates Six1 treatment; blue shows Eya1 and green Six1+Eya1. Enrichment scores ≥1.5 are reported for individual treatment groups (Ind.) and, where available, ≥0.5 for merged treatment groups (Merg.). (**A**) Down-regulated genes from all treatment groups included in analysis; (**B**) *Six1* overexpression only; (**C**) *Eya1* overexpression only. (**D**) Genes differentially expressed after overexpression of both *Six1* and *Eya1*; (**E**) exclusively after *Six1* overexpression.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.006](10.7554/eLife.17666.006)

GSEA analysis of discrete subsets of genes exclusively regulated by Six1 or Eya1 suggested that they also regulate some categories of genes independently of one another. A particularly interesting finding was the extreme enrichment of *Hox* genes (specifically of the Antennapedia-type) in the Eya1-specific subset of up-regulated genes ([Figure 3F](#fig3){ref-type="fig"}), suggesting that Eya1 may play a previously un-identified role in regulating Hox gene expression independently of Six1.

Characterisation of transcriptional regulators activated by Six1 or Eya1 {#s2-5}
------------------------------------------------------------------------

To verify our RNA-Seq data, we selected a number of target genes for further characterisation and, in order to gain insight into the GRN downstream of Six1 and Eya1, we restricted candidates to transcription factors or co-factors up-regulated by Six1 or Eya1. First, we generated a list of well-supported target genes containing all genes with at least a two-fold up-regulation in at least two of our three treatment groups ([Table 1](#tbl1){ref-type="table"}). From the 228 genes in this list we selected all 30 transcription factors or co-factors for further analysis. However, we were unable to amplify two genes from this list (*Egr3, Fbxo41*) from cDNA and therefore omitted these genes from further characterisation. We additionally included *Sox3* and *Ngn1* - which were found to be slightly below our threshold of twofold up-regulation in at least two treatment groups - because previous studies have implicated these genes in the regulation of placodal neurogenesis downstream of Six1 and Eya1 ([@bib61], [@bib60]; [@bib87]; [@bib3]) ([Table 2](#tbl2){ref-type="table"}).10.7554/eLife.17666.007Table 1.Genes with at least two-fold up-regulation in at least two out of three individual treatment groups (Six1~i~; Eya1~i~; Six1+Eya1~i~).**DOI:** [http://dx.doi.org/10.7554/eLife.17666.007](10.7554/eLife.17666.007)Annotation\*AccessionSix1 FC^†^Eya1 FC^‡^Six1+Eya1 FC^§^Chromosome unknown open reading frameXM_002938866.26.2-7.9cDNA clone IMAGE:7022272BC094950.15.65.17.5*X. laevis* cyclin Dx (ccndx)NP_001087887.17.5-5.2Calcitonin gene-related peptide-likeXM_002941675.27-3*X. laevis* tripartite motif containing 63, E3 ubiquitin protein ligase (trim63)NM_001093214.15.33.66.3ATP-sensitive inward rectifier potassium channel 11-likeXM_004916278.15.1-6.1Leucine rich repeat containing 52 (lrrc52)XM_002933773.26.1-2.8\#SIX homeobox 2 (six2)NM_001100275.153.55.9Potassium voltage-gated channel shaker-related subfamily member 2 (kcna2)XM_004910736.15.1-4.9Butyrophilin subfamily 2 member A1 (btn2a1)NM_001094508.1-1.24.9Glutathione peroxidase 2 (gpx2)NM_001256315.1-2.54.8\#*X. laevis* for Xsox17-alpha proteinAJ001730.13.62.64.8*X. laevis* ectodysplasin A receptor (edar)NM_001087047.12.82.54.7Uncharacterized (LOC101734405)XM_004918247.14.40.83.5Glutathione peroxidase 2 (gpx2)NM_001256315.13.42.14.4*X. laevis* cytochrome P450, family 2, subfamily D, polypeptide 6 (cyp2d6)NM_001093574.11.1-4.4Calcium/calmodulin-dependent protein kinase kinase 2beta (camkk2)XM_002937701.24.42.63.5Cytochrome P450 family 26 subfamily B polypeptide 1 (cyp26b1)NM_001079187.23.344.3Troponin I type 1 (skeletal, slow)BC0612681.8-4.372 kDa inositol polyphosphate 5-phosphatase-like (LOC101734556)XM_004916572.1-4.21.3Chemokine (C-X-C motif) receptor 7 (cxcr7)NM_001030434.132.84.1\#*X. laevis* xSox17 alpha 2AB052691.11.71.44Espin (espn) transcript variant X3XM_004916193.1-2.14B-cell CLL/lymphoma 11B (zinc finger protein) (bcl11b)XM_004917116.1-1.94C-X-C motif chemokine 10-likeXM_002940578.21.943.5*X. laevis* hedgehog-interacting proteinBC046952.1-2.74X-linked inhibitor of apoptosis (xiap)NM_001030412.143.12.3*X. laevis* uncharacterized (LOC496300)NM_001095458.11.43.91.1*X. laevis* RDC1 like proteinBC098974.13.62.13.9*X. laevis* for frizzled 4 protein (fz4 gene)AJ251750.11.30.63.8Espin (espn) transcript variant X1XM_002933856.23.12.73.7Paired box 1 (pax1) transcript variant X1JQ929179.1-33.7Potassium voltage-gated channel subfamily F member 1 (kcnf1)NM_001102926.13.6-2.1Echinoderm microtubule-associated protein-like 1-likeXM_004917169.1-3.62.8Leucine rich adaptor protein 1-like (lurap1l)XM_002940127.23.61.42.4Sine oculis binding protein homolog (Drosophila)BC154687.12.71.63.4RNA-directed DNA polymerase homologXM_004916122.13.4-2.1Kinesin family member 3C (kif3c) transcript variant X1XM_004914940.11.40.83.4Anoctamin 2 (ano2)XM_002932297.22.21.33.4*X. laevis* natriuretic peptide C (nppc)NM_001112924.12.1-3.3Uncharacterized (LOC101734952)XM_004916172.12.5-3.3Poly (ADP-ribose) polymerase 14-like (LOC101731378)XM_004920062.13.1-3.3Protocadherin-11 X-linked-like (LOC100493938)XM_004916890.1-3.21.4Uncharacterized (LOC101733225)XM_004919937.12.53.21.6Calcium channel voltage-dependent beta 4 subunit (cacnb4)NM_001142151.13.1-1.9F-box protein 32 (fbxo32) transcript variant X1XM_002941397.21.8-3.1cDNA clone TEgg026p17CR761997.232.6-*X. laevis* transforming growth factor beta-induced (tgfbi)NM_001095238.11.3-3Mucin-2-like (LOC100494747)XM_002936043.2321.7*X. laevis* uncharacterized protein (MGC68450)NM_001089841.12.2-2.8*X. laevis* neuregulin alpha-1AF076618.11.40.82.7Potassium voltage-gated channel Isk-related (kcne1)XM_004912135.12.21.52.7Olfactory receptor 5G3-like (LOC100492086)XM_002942220.11.9-2.7Alpha-kinase 2 (alpk2)XM_004910401.11.12.22.7*X. laevis* arginyl amino peptidase (amino peptidase B) b (rnpep-b)NM_001092079.1-2.71.7\#*X. laevis* SRY-box containing protein (Sox1)EF672727.1-2.62.1Copine II (cpne2) transcript variant X1XM_004913481.111.22.6*X. laevis* hemoglobin, gamma A (hbg1)NM_0010963471.2-2.6KIAA0895 protein (kiaa0895)NM_001114073.11.62.6-\#*X. laevis* empty spiracles homeobox 1gene 2 (emx1.2)NM_001093430.12.61.91.1Homeobox B8 (hoxb8) transcript variant X1XM_002938021.21.12.5-Monocyte to macrophage differentiation-associated (mmd)XM_004918560.1-1.22.5*X. laevis* uncharacterized (LOC100036933)NM_001097704.11.51.52.5Finished cDNA clone TNeu143f19CR760056.22.22.5-Chromosome unknown open reading frame C2orf80XM_002937119.21.42.12.4\#Single-minded homolog 1 (sim1) transcript variant X2XM_004914545.1-1.42.4Transmembrane protein 2-like (LOC100491930)XM_002932255.22.41.91.3PX domain containing 1 (pxdc1)NM_001130262.11.4-2.4Aldehyde dehydrogenase 1 family member L2 (aldh1l2)XM_002938070.20.91.32.3Uncharacterized (LOC100490228)XM_002942932.21.8-2.3Beta-1 3-galactosyltransferase 2-like (LOC101732799)XM_004918863.11.62.3-Alpha-2 3-sialyltransferase ST3Gal V (st3gal5)FN550108.11.8-2.3*X. laevis* uncharacterized protein (MGC64538)NM_001086337.1-1.62.3Transmembrane channel-like protein 7-like (LOC100493700)XM_002932222.21.40.92.3Kinase insert domain receptor (a type III receptor tyrosine kinase) (kdr)XM_002934669.21.90.92.3Serine/threonine kinase 32A (stk32a)XM_002936707.21.32.2-Pancreatic lipase-related protein 2 (pnliprp2)NM_001089647.12.10.72.2*X. laevis* nephrin (NPHS1)AY902238.1-2.21.1Poly (ADP-ribose) polymerase 14-like (LOC100485144)XM_002943546.222.21.2Frizzled family receptor 4 (fzd4)XM_002936543.21.40.72.1Neuropeptide Y receptor Y2 (npy2r)XM_004911153.12.1-1.6Deoxyribonuclease gamma-like (LOC100497175)XM_002938386.21.82.12*X. laevis* dehydrogenase/reductase (SDR family) member 11 (dhrs11)NM_001094963.1-1.52.1*X. laevis* gamma-glutamyl hydrolase (ggh)NM_001092691.12.11.32Opsin-3-likeXM_002932623.211.22*X. laevis* transmembrane protein 56 (tmem56-b)NM_001086447.1-1.12*X. laevis* pyruvate dehyrogenase phosphatase catalytic subunit 1 (pdp1)NM_001094221.11.521ArfGAP with SH3 domain ankyrin repeat and PH domain 3 (asap3)XM_002939360.21.7-1.9\#Early growth response 3 (egr3)XM_002932703.21.60.81.9\#POU class 4 homeobox 1 (pou4f1.2)NM_001097307.11.311.9Activin beta B subunitS61773.1-1.71.8Monocyte to macrophage differentiation-associated (mmd)XM_002937811.21.71.11.8*X. laevis* ribosomal protein S2eBC130122.1-1.81.7*X. laevis* ras homolog family member V (rhov)NM_001128659.11.20.81.6*X. laevis* adenomatosis polyposis coli down-regulated 1 (apcdd1)NM_001094109.11.211.6\#*X. laevis* zinc finger protein 214 (znf214)NM_001097042.11.20.81.5*X. laevis* cdc25BaAB363840.11.2-1.5*X. laevis* apelin (apln-a)NM_001097924.10.91.31.5Suppressor of cytokine signaling 2 (socs2)NM_001095760.1-1.11.5\#cAMP responsive element modulator (crem)XM_002935162.2-1.41.5*X. laevis* clone IMAGE:4684003BC042305.11.4-1.2\#*X. laevis* ets-2a proto-oncogeneBC133183.11.311.4*X. laevis* similar to envoplakinBC045116.11.41.4-Ras homolog family member V (rhov)NM_001095566.11.411.2Samd9l protein (samd9l)XM_002943522.2-1.21.3Flocculation protein FLO11-like (LOC100490389)XM_002942555.21.2-1.3c-Jun-amino-terminal kinase-interacting protein 4-like (LOC100493724)XM_002939963.21.1-1.2*X. laevis* Dickkopf-1 (Xdkk-1)AF030434.111.21.1*X. laevis* ectoderm neural cortex related-3 (Encr-3)AY216793.11.10.81.2Uncharacterized (LOC101730819)XM_004915204.10.91.11.2\#*X. laevis* LIM class homeodomain proteinBC084744.11.10.71.1Ceramide kinase-like (cerkl)XM_002932015.21.41.32Mannosyl (alpha-1 3-)-glycoprotein beta-1 4-N-acetylglucosaminyltransferase (mgat4b)NM_001091975.12-1.8Fibroblast growth factor 19 (fgf19)NM_001142825.1-21.5\#F-box protein 41 (fbxo41)NM_001079043.11.30.62Avidin-like (LOC100487365)XM_002939983.221.6-Four and a half LIM domains 2 (fhl2)NM_001126761.1-1.11.9Metalloprotease TIKI1-like (LOC100491951)XM_002936336.21.11.41.9*X. laevis* Kazal-type serine peptidase inhibitor domain 1 (kazald1)NM_001092073.11.61.11.9Uncharacterized (LOC101734664)XM_004910525.11.20.61.9*X. laevis* similar to calsequestrin 2 (cardiac muscle)BC097545.11.81.51.9*X. laevis* COMM domain containing 3 (commd3)NM_001095386.11.11.90.6*X. laevis* alcohol dehydrogenase iron containing1 (adhfe1)NM_001127802.1-1.91.2*X. laevis* ectonucleoside triphosphate diphosphohydrolase 1 (entpd1)NM_001092268.11.80.61.3\#Protein fosB-like transcript variant X2XM_004916957.1-1.71.4Tocopherol (alpha) transfer protein (ttpa)NM_001008184.1-1.71.6*X. laevis* tetratricopeptide repeat domain 39B (ttc39b)NM_001094701.11.1-1.7\#*X. laevis* Tbx6 (Tbx6)DQ355794.11.41.71*X. laevis* uncharacterized (LOC100036989)NM_001097746.1-1.31.7*X. laevis* cDNA clone IMAGE:6947552BC093552.11.31.7-B-cell CLL/lymphoma 10 (bcl10)NM_001015777.21.7-1.2Uncharacterized (LOC100494710)XM_002939048.21.41.6-*X. laevis* keratin 17 (krt17)NM_001094941.1-1.21.6Membrane metallo-endopeptidase-like 1 (mmel1)NM_001127095.10.91.11.6Putative methyltransferase KIAA1456 homologXM_002934674.21.1-1.6Phospholipase Cdelta 3 (plcd3)XM_002935518.21.11.51.6IdnK gluconokinase homolog (E. coli) (idnk)NM_001126592.11.40.91.5Uncharacterized (LOC100486093) transcript variant X2XM_002939117.21.5-1.5*X. laevis* similar to calsequestrin 2 (cardiac muscle)BC041283.11.1-1.5Piwi-like RNA-mediated gene silencing 2 (piwil2)NM_001112999.11.1-1.5Zinc finger and BTB domain containing 20 (zbtb20)XM_002939649.21.4-1.1\#V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (mafa)NM_001032304.11.40.91.1*X. laevis* uncharacterized protein (MGC81120)NM_001091225.11.40.91.3\#Single-minded homolog 1 (*Drosophila*) (sim1) transcript variant X3XM_004914546.11.11.31.2Xenopus laevis alpha-2-macroglobulin-like 1 (a2ml1)NM_001135077.11.1-1.1*X. laevis* chromogranin A (parathyroid secretory protein 1) (chga)NM_001094724.11.61.42.2*X. laevis* lipaseendothelial (lipg)NM_001090061.11.21.30.6G protein-coupled receptor 56 (gpr56)XM_002931653.21.7-1.6*X. laevis* family with sequence similarity 101member B (fam101b)NM_001093870.11.50.81.5*X. laevis* CD81 protein (cd81-a)NM_001086613.10.71.11.9*X. laevis* calbindin D28kBC170542.12.2-3.1*X. laevis* ATPaseNa+/K+ transportingbeta 1 polypeptide (atp1b1)NM_001086759.11.211.7*X. laevis* 7-transmembrane receptor frizzled-1AF231711.11.412*X. laevis* prostaglandin reductase 2 (ptgr2)NM_001079334.11.41.5-*X. laevis* TGF-beta2 for transforming growth factor-beta2X51817.11.3-1.1\#SRY (sex determining region Y)-box 2 (sox2)NM_213704.31.11.31.9\#*X. laevis* for enhancer of split related 9 (esr9 gene)AJ009282.11.71.6-*X. laevis* mal T-cell differentiation protein (mal)NM_001086577.1-1.21.4Transmembrane proteaseserine 13 (tmprss13)XM_002932904.21.51.11.9*X. laevis* Ras-related associated with diabetes (rrad)NM_001092750.184.64.2Integrin beta 4 (itgb4) transcript variant X1XM_002939974.21.4-2.2*Xenopus (Silurana) tropicalis* FERM domain containing 4A (frmd4a)XM_002935243.21.10.61.3*X. laevis* complement factor I (cfi-a)NM_001085952.11.41.21.6\#*X. laevis* SIX homeobox 1 (six1)NP_001082027.11.41.22.3FH2 domain-containing protein 1-like (LOC100496216)XM_002934907.21.90.91.9\#*X. laevis* mab-21-like 2 (mab21l2-b)NM_001096770.1-2.82.9*X. laevis* regulator of cell cycle (rgcc)NM_001093976.11.31.11.7*X. laevis* Cep63FJ464988.1-1.42.3*X. laevis* CD81 antigen (target of anti proliferative antibody 1)BC041217.11.71.12Transmembrane serine protease 9BC087611.11.11.11.2\#*X. laevis* POU class 3 homeobox 2 (pou3f2-b)NM_001096751.132.32.9G protein-coupled receptor 153 (gpr153)NM_001128052.12.51.11.5\#*X. laevis* Myoblast determination protein 1 homolog ABC041190.13.52.74.7\#T-cell leukemia homeobox 1 (tlx1) transcript variant 1XM_002936768.22.62.32.6*X. laevis* neurotrophin 3 (ntf3)NM_001092740.11.41.51.9*X. laevis* p21 GTPase-associated kinase 1 (PAK1)AF000239.11.2-2.1\#*X. laevis* hairy and enhancer of split 9, gene 1 (hes9.1-b)NP_001089097.11.81.51.6*X. laevis* tetraspanin 1 (tspan1)NM_001095473.11.20.71.3*X. laevis* uncharacterized protein (MGC83079)NM_001091250.121.5-*X. laevis* cDNA clone IMAGE:5085355BC073731.11.3-1.4Family with sequence similarity 198member A (fam198a)XM_002937853.21.70.71.3Progestin and adipoQ receptor family member IX (paqr9)XM_004914351.11.7-1.2\#Hairy and enhancer of split 8 (hes8)XM_002933849.22.81.73.6*X. laevis* p21 GTPase-associated kinase 1BC081113.11.30.81.7Finished cDNA clone TNeu008g03CR761907.21.21.10.7WD repeat domain 27 (wdr27)XM_002931515.21.22.21.1\#Growth factor independent 1 transcription repressor (gfi1)XM_002933803.21.81.83.2Protein phosphatase 2 regulatory subunit B\'beta (ppp2r5b)NM_001100279.12.41.44.2Ornithine decarboxylase antizyme 2 (oaz2), transcript variant 2NP_001106583.21.8-1.5*X. laevis* fast troponin T (TNNT3)AY114144.1-1.11.5\#*X. laevis* xRipply3 for xRipply3 proteinAB455086.10.91.12RAS-like family 11member B (rasl11b)NM_001015774.1-1.21.4*X. laevis* for thimet oligopeptidaseBC070748.13.8-2*X. laevis* fibroblast growth factor 3 (fgf3)NM_001008153.121.22*X. laevis* cDNA clone IMAGE:8332229BC155363.11.50.91.4Proline rich 15 (prr15)XM_002933381.21.6-1.3Integrin beta 6 (itgb6)NM_001097306.12.30.62.8\#*Xenopus laevis* empty spiracles homeobox 1, gene 2 (emx1.2)NM_001093430.12.61.42.1*X. laevis* p21-activated kinase (PAK1)AF169794.11.41.82.6\#ISL LIM homeobox 2 (isl2)NM_001166041.11.5-1.7\#Atonal homolog 1 (Drosophila) (atoh1)XM_004911085.10.91.11.5Ectodysplasin A receptor (edar)NM_001087047.14.3-3.3*X. laevis* degr03DQ096846.12.12.22Calcyphosine (caps)NM_001097320.1-1.43.7*X. laevis* kiaa0930NM_001086221.11.511.6Putative N-acetyltransferase 16-like (LOC100490742)XM_002943189.12.111.7\#T-box 15 (tbx15)XM_002940981.2211.8\#SRY (sex determining region Y)-box 1 (sox1)NM_001080996.10.61.51.2Cytochrome P450 family 2 subfamily C polypeptide 18 (cyp2c18)NM_001091776.12.11.41.6*X. laevis* calcitonin receptor-like (calcrl)NM_001086737.11.10.81.6*X. laevis* claudin 3 (cldn3)NM_001005709.12.11.31.5Atlastin GTPase 1 (atl1)NM_001078754.11.821.7Rho GTPase activating protein 9 (arhgap9), transcript variant X2XM_0129578291.81.23.4\#*X. laevis* Hes2BC084134.11.70.91.3*X. laevis* U3 snRNAX07318.112.81.1Uncharacterized (LOC101732195)XM_004912378.12-1.5Tumor necrosis factor receptor superfamilymember 21 (tnfrsf21)NM_001079136.11.10.81.2*X. laevis* arginase 3U08408.1-1.31.8ChaC cation transport regulator homolog 1 (chac1)XM_002939546.21.21.31.5*X. laevis* DIRAS familyGTP-binding RAS-like 3 (diras3)NM_001095243.10.81.71.4*X. laevis* DnaJ (Hsp40) homolog subfamily C member 27 (dnajc27-b)NM_001095422.11.10.81.1[^1][^2][^3][^4][^5]10.7554/eLife.17666.008Table 2.Transcription factors and co-factors selected for characterisation by in-situ-hybridisation ranked by FC value in individual treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.008](10.7554/eLife.17666.008)AnnotationGeneAccessionIndividualMergedSix1\*Eya1^†^Six1+Eya1^‡^Six1^§^Eya1^\#^Six1+Eya1^¶^SIX homeobox 2 (Six2)Six2NM_001100275.153.55.95.4\*\*5\*\*4.9\*\**X. laevis* for Xsox17-alpha proteinSox17AJ001730.13.62.64.84.4\*\*3.3\*\*3.5\*\**X. laevis* Myoblast determination protein 1 homolog AMyoD1BC041190.13.52.74.74.1\*\*4.2\*\*3.9\*\*Hairy and enhancer of split 8 (Hes8)Hes8XM_002933849.22.81.73.63.2\*\*3.2\*\*3.1\*\*Growth factor independent 1 transcription repressor (Gfi1)Gfi1aXM_002933803.21.81.83.22.4\*\*2.6\*\*4.1\*\**X. laevis* POU class 3 homeobox 2 (Pou3f2-b)Pou3f2bNM_001096751.132.32.93\*\*2.6\*\*2.7\*\**X. laevis* Mab-21-like 2 (Mab21l2-b)Mab21l2bNM_001096770.1-2.82.9\-\--T-cell leukemia homeobox 1 (Tlx1) transcript variant 1Tlx1XM_002936768.22.62.32.62.4\*\*2.4\*\*2.4\*\**X. laevis* empty spiracles homeobox 1 gene 2 (Emx1.2)Emx1.2NM_001093430.12.61.91.1\--1.7\*\**X. laevis* SRY-box containing protein (Sox1)Sox1EF672727.1-2.62.1-2\*\*-Single-minded homolog 1 (Sim1) transcript variant X2Sim1XM_004914545.1-1.42.4\-\--*X. laevis* SIX homeobox 1 (Six1)Six1AF279254.11.41.22.31.9\*\*1.6\*\*1.6\*\*F-box protein 41 (Fbxo41)Fbxo41NM_001079043.11.30.62\-\--T-box 15 (Tbx15)Tbx15XM_002940981.2211.82\*\*1.4\*\*1.7\*\**X. laevis* xRipply3 for xRipply3 proteinRipply3AB455086.10.91.121.6\*\*1.4\*\*1.3\*\*Early growth response 3 (Egr3)Egr3XM_002932703.21.60.81.91.7\*\*1.3\*\*1.9\*\*SRY (sex determining region Y)-box 2 (Sox2)Sox2NM_213704.31.11.31.91.6\*\*1.6\*\*1.5\*\*POU class 4 homeobox 1 (Pou4f1.2)Pou4f1.2NM_001097307.11.311.91.6\*\*1.5\*\*1.5\*\**X. laevis* for enhancer of split related 9 (Esr9 gene)Hes9.1aAJ009282.11.71.6\-\-\--ISL LIM homeobox 2 (Isl2)Isl2NM_001166041.11.5-1.71.6\*\*1.1\*\*1.4\*\**X. laevis* Tbx6 (Tbx6)Tbx6DQ355794.11.41.71\-\--Protein FosB-like transcript variant X2FosBXM_004916957.1-1.71.4-1.4\*\*1.2\*\**X. laevis* Hes2Hes2BC084134.11.70.91.3\-\--cAMP responsive element modulator (Crem)CremXM_002935162.2-1.41.5-1.4\*\*1.2\*\**X. laevis* zinc finger protein 214 (Znf214)Znf214NM_001097042.11.20.81.51.2\*\*5.9\*\*5.8\*\**Xenopus laevis* SRY (sex determining region Y)-box 21 (Sox21)Sox21NM_001172213.11.20.61.51.4\*\*1.2\*\*1.2\*\*Atonal homolog 1 (*Drosophila*) (Atoh1)Atoh1XM_004911085.10.91.11.5111*X. laevis* Ets-2a proto-oncogeneEts2aBC133183.11.311.41.3\*\*1.2\*\*1.2\*\*V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (Mafa)MafaNM_001032304.11.40.91.11.9\*\*-1.8\*\**X. laevis* LIM class homeodomain proteinLhx5BC084744.11.1-1.1\-\--*Xenopus (Silurana) tropicalis* neurogenin 1 (Neurog1)Ngn1NM_001123423.10.80.90.80.80.80.8\*\**Xenopus laevis* SOX3 proteinSox3BC072222.10.5-0.90.70.70.6[^6][^7][^8][^9][^10][^11][^12]

The expression of genes previously undescribed in *Xenopus (Crem, FosB, Hes8, Isl2, Tbx15, Znf214*) was fully characterised in neural fold, and early and late tail bud stages, along with those for which expression has been described for relatively few stages (*Atoh1, Emx1.2, Gfi1a, Hes2, Hes9, Lhx5, Mab21l2b, Pou3f2b, Pou4f1.2, Ripply3, Sim1, Sox21, Tbx6, Tlx1*) (summarised in [Figure 4A--T](#fig4){ref-type="fig"}; [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}--[5](#fig4s5){ref-type="fig"}). Genes with extensively characterised expression patterns (*Ngn1* ([@bib69])*; Six1* ([@bib75]); *Six2* ([@bib29]); *Sox2* ([@bib67]); *Sox3* ([@bib77]); *Sox17* ([@bib41]), *MyoD1* ([@bib38]), *Sox1* ([@bib71]), *Ets2a* ([@bib84]), *Mafa* ([@bib21])) are not shown here.10.7554/eLife.17666.009Figure 4.Expression of selected presumptive direct targets of Six1/Eya1 in whole-mount *Xenopus* embryos.Genes expressed at neural plate stages (stages 14--18) are shown in panels **A**--**L**, and those only expressed at later stages are shown at mid/late tail bud stage (stages 28--32) in panels **M**--**T**. Several of the genes surveyed (*Lhx5, Pou3f2b, Tbx15, Tbx6, Emx1.2* and *Sim1* (**A**--**D**, **M** and **N**), were not expressed in the PPE, nor any placodal derivatives in later stages. Instead, such genes were expressed in the adjacent neural folds (*Lhx5, Pou3f2b and Tbx15*), ectoderm (*Tbx6),* or in the forebrain at later stages (*Emx1.2*). Several other genes were expressed broadly across the cranial ectoderm, at least partially overlapping with the PPE at neural plate stages (*Ripply3, Crem, FosB* and *Znf214*; **E**,**O**--**Q**), some of which are also maintained in placodal derivatives such as *Znf214* in the otic vesicle (**Q**). The remaining genes (**F**--**L**, **R**--**T**) are expressed in parts of the PPE and maintained in some placodes (*Hes2, Hes8, Hes9, Mab21l2b, Sox21, Isl2, Pou4f1.2,* and *Tlx1)* or are expressed in a subset of placodes only (*Atoh1, Gfi1a) (*see [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}--[4](#fig4s4){ref-type="fig"} for additional stages). Yellow arrows mark placodal expression. Arrowheads mark non-placodal expression. Abbreviations: pA: anterior placodal region; pAD: anterior lateral line placode; pE: epibranchial placode; pL: lens placode; L: lens; pM: middle lateral line placode; pO: olfactory placode; pP: posterior placodal region; pPrV: profundal/trigenimal placodes; vOt: otic vesicle. Plots **U** and **V** show qPCR after *Six1* or *Eya1* overexpression. Log~2~ fold change values were calculated from qPCR data obtained after overexpression of Six1-GR (**U**) or Eya1-GR (**V**) in placodal explants and are shown next to corresponding fold change values obtained from the RNA-Seq data. In all cases shown, qPCR values broadly corroborate those from the RNA-Seq data - showing up-regulation of target genes after either *Six1* or *Eya1* overexpression. Vertical error bars show the standard deviation of the mean of biological triplicates.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.009](10.7554/eLife.17666.009)10.7554/eLife.17666.010Figure 4---figure supplement 1.Expression of targets not expressed in placodes in whole-mount *Xenopus* embryos.Expression dynamics for each target are shown across a range of developmental stages: **A**~**1**~--**F**~**1**~ show expression in neural plate stage embryos, **A**~**2**~--**F**~**2**~ show early tail bud stage embryos and **A**~**3**~--**F**~**3**~ show late tail bud stage embryos. (**A**) Expression of PPE marker gene *Six1* is shown as reference for placodal domains (for details see [@bib75]; [@bib86]). (**B**) *Emx1.2* is expressed broadly in the neural plate in neural plate stages (**B~1~**), and becomes restricted to the forebrain in late tail bud stages (**B**~**3**~; asterisk). (**C**) *Lhx5* is expressed in the forebrain at all developmental stages (**C~1~**--**C**~**3**~; asterisk), and at early and late tail bud stages *Lhx5* is also expressed in the hindbrain and spinal cord (**C**~**3**~; arrowhead). (**D**) *Pou3f2b* is expressed in the neural plate and developing neural tube (**D**~**1**~; asterisk) at neural plate stages. Expression in the brain and spinal cord is maintained during early and late tail bud stages (**D**~**2**~ and **D**~**3** ~; arrowhead and asterisk, respectively). (**E**) *Tbx15* is expressed in a restricted domain of the anterolateral neural folds in neural plate stages (**E~1~**; asterisk). At tail bud stages expression is prominent in somites (**E**~**2** ~and **E**~**3**~; arrowhead) and migrating neural crest cells of the hyoid and first branchial neural crest streams (Nc). Both of these expression domains are maintained into late tail bud stages (**E~3~** and **E**~**4**~). **E~4~** shows section at the level indicated in **E**~**3**~ (dotted line). Bar in **E**~**4**~: 100 μm. (**F**) Throughout all developmental stages (**F~1~**--**F**~**3**~) *Tbx6* is expressed strongly in the posterior paraxial and lateral plate mesoderm (**F~1~** and **F**~**2**~; asterisk) with weaker expression in the pharyngeal arches (**F~2~**; arrowhead). Subsequently, it's expressed in somites, as indicated by a diamond in **F**~**2**~. Abbreviations: pA: anterior placodal region; pAD: anterior lateral line placode; pE: epibranchial placode; pM: middle lateral line placode; pO: olfactory placode; vOt: otic vesicle; pPrV: profundal/trigeminal placodes.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.010](10.7554/eLife.17666.010)10.7554/eLife.17666.011Figure 4---figure supplement 2.Expression of targets that broadly overlap with PPE in whole-mount *Xenopus* embryos.Expression dynamics for each target are shown across a range of developmental stages: **A~1~**--**E**~**1**~ show expression in neural plate stage embryos, **A**~**2**~--**E**~**2**~ show early tail bud stage embryos and **A**~**3**~--**E**~**3**~ show late tail bud stage embryos. (**A**) Expression of PPE marker gene *Six1* is shown as reference for placodal domains (for details see [@bib75]; [@bib86]). (**B**) *Crem* is initially expressed broadly in paraxial mesoderm (**B**~**1**~; asterisk) and cranial ectoderm (**B**~**1**~; arrowhead) at neural plate stages and in pharyngeal arches and overlying ectoderm at early and late tail bud stages (**B**~**2**~ and **B**~**3** ~; diamond). (**C**) *FosB* is expressed in a broad pattern across the cranial ectoderm and trunk mesoderm at both neural fold and early tail bud stages (**C**~**1**~and **C**~**2**~). At late tail bud stages expression is maintained in cranial ectoderm as well as becoming apparent in the migrating neural crest cells (Nc) and weakly in the somites (**C**~**3**~; arrowhead). (**D**) *Znf214* is expressed broadly across the ectoderm at all developmental stages (**D**~**1**~--**D**~**3**~). At both early and late tail bud stages there is expression in the migrating neural crest cells (Nc) as well as in the retina (**D**~**2** ~and **D**~**3**~; asterisk), and in late tail bud stages *Znf214* is expressed in the otic vesicle and lens. (**E**) *Ripply3* is expressed broadly in the posterior placodal region at neural fold stages (**E~1~**). At both early and late tail bud stages expression is confined to posterior cranial ectoderm (**E**~**2 **~and **E**~**3**~; asterisk). Yellow arrows mark placodal expression. Abbreviations: pA: anterior placodal region; pAD: anterior lateral line placode; pE: epibranchial placode; L: lens; pM: middle lateral line placode; pO: olfactory placode; vOt: otic vesicle; pP: posterior placodal region; pPrV: profundal/trigeminal placodes.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.011](10.7554/eLife.17666.011)10.7554/eLife.17666.012Figure 4---figure supplement 3.Expression of targets with dynamic/transient expression pattern in placodes in whole-mount *Xenopus* embryos.Expression dynamics for each target are shown across a range of developmental stages: **A**~**1**~--**E**~**1**~ show expression in neural plate stage embryos, **A**~**2**~--**E**~**2**~ show early tail bud stage embryos and **A**~**3**~--**E**~**3**~ show late tail bud stage embryos. (**A**) Expression of PPE marker gene *Six1* is shown as reference for placodal domains (for details see [@bib75]; [@bib86]). (**B**) *Hes2* is expressed very strongly in a broad region corresponding to the posterior placodal domain including the prospective otic and lateral line placodes, as well as weakly in a scattered subset of neuroectodermal cells (**B**~**1**~; asterisk) at neural plate stages (see [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"} for section). Expression is later restricted to the otic vesicle and a new expression domain becomes established in the developing retina at early and late tail bud stages (**B**~**2**~ and **B**~**3**~; arrowhead). (**C**) During neural plate stages (**C**~**1**~), *Hes8* is expressed in the developing profundal and trigeminal placodes as well as in the anterior placodal region, the anterior neural plate (**C**~**1**~ ; asterisk) and the primary neurons (motor neurons, intermediary neurons and sensory neurons) of the posterior neural plate (**C**~**1**~; arrowheads; see [Figure 4--- figure supplement 5](#fig4s5){ref-type="fig"} for section). In early tail bud stages (**C**~**2**~) trigeminal expression is lost and replaced by expression in the otic vesicle, as well as lateral line, epibranchial and olfactory placodes. Throughout late tail bud stages (**C**~**3**~), expression is maintained in these regions and the brain (**C**~**3**~; cross) and is initiated in the retina (**C**~**3**~; diamond). (**D**) During neural plate stages (**D**~**1**~), *Hes9* is expressed in the developing profundal and trigeminal placodes as well as in the anterior placodal region, the anterior neural plate (**D**~**1**~; asterisk) and the primary neurons (motor neurons, intermediary neurons and sensory neurons) of the posterior neural plate (**D**~**1**~; arrowheads; see [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"} for section). In early tail bud stages (**D**~**2**~) trigeminal expression is lost but expression is apparent in the olfactory placodes, as well as in the otic and lateral line placodes and retina (**D**~**2**~; diamond). In late tail bud stages (**D**~**3**~) *Hes9* is expressed broadly thoughout the brain (**D**~**3** ~; cross), and is maintained in the lateral line and olfactory placodes as well as the otic vesicle. (**E**) During neural plate stages (**E**~**1**~), *Mab21l2b* is expressed in the prospective lens placode, as well as in the eye field (prospective retina) of the forebrain (**E**~**1**~; asterisk) and the prospective midbrain (**E**~**1**~; arrowhead). At early tail bud stages expression in the lens and midbrain is maintained and its expression becomes apparent in the hindbrain (**E**~**2**~; diamond). In late tail bud stages *Mab21l2b* is additionally prominently expressed in migrating neural crest cells (**E**~**3**~ ; Nc). (**F**) During neural plate stages *Sox21* is expressed broadly throughout the anterior neural plate (**F**~**1**~; asterisk). At early tail bud stages (**F**~**2**~), this expression becomes confined to the forebrain (asterisk in **F**~**2**~) and midbrain-hindbrain boundary (arrowhead in **F**~**2**~) and is maintained into late tail bud stages, (**F**~**3**~). In late tail bud stages, *Sox21* is also expressed in the olfactory placode, otic vesicle and becomes up-regulated in the hindbrain (**F**~**3**~; diamond). Yellow arrows mark placodal expression. Dotted lines in **B**~**1**--~**D**~**1**~ indicate levels of sections shown in [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}. Abbreviations: pA: anterior placodal region; pAD: anterior lateral line placode; pE: epibranchial placode; pLl: lateral line placodes; L: lens; pL: lens placode; pM: middle lateral line placode; pO: olfactory placode; vOt: otic vesicle; pP: posterior placodal region; pPrV: profundal/trigeminal placodes.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.012](10.7554/eLife.17666.012)10.7554/eLife.17666.013Figure 4---figure supplement 4.Expression of targets with persistent expression in placodes in whole-mount *Xenopus* embryos.Expression dynamics for each target are shown across a range of developmental stages: **A**~**1**--~**F**~**1**~ show expression in neural plate stage embryos, **A**~**2**~--**F**~**2**~ show early tail bud stage embryos and **A**~**3**~--**F**~**3**~ show late tail bud stage embryos. **B**~**4**~--**D**~**4**~ and **B**~**5**~ --**D**~**5**~ shows sections at level indicated in **B**~**3**--~**D**~**3**~, respectively (dotted lines). (**A**) Expression of PPE marker gene *Six1* is shown as reference for placodal domains (for details see [@bib75]; [@bib86]). (**B**) *Atoh1* is initially expressed at very low levels in presumptive otic placodes at neural plate stages (**B**~**1**~). This expression becomes more pronounced in the otic vesicle at early tail bud stages (**B**~**2**~) concomitant with the initiation of expression in lateral line ganglia and strong expression in the hindbrain (**B**~**2**~; asterisk). Expression becomes more pronounced in all three regions at late tail bud stages (**B**~**3**~ --**B**~**5**~). (**C**) *Gfi1a* is expressed at high levels in haematopoietic cells during neural plate stages (**C**~**1**~; asterisk). At early tail bud stages (**C**~**2**~) expression becomes more pronounced and diffuse, and expression is also initiated in the otic vesicle. At late tail bud stages *Gfi1a* is expressed in lateral line placodes as well as otic vesicles as the haematopoietic expression begins to subside (**C**~**3**~--**C**~**5**~). (**D**) During neural plate stages *Isl2* is expressed in the profundal and trigeminal placodes and in the anterior placodal region along the anterior edge of the neural plate (**D**~**1**~). At early tail bud stages *Isl2* expression is maintained in the profundal and trigeminal placodes/ganglia as well as in otic and lateral line placodes/ganglia and primary neurons in the spinal cord (**D**~**2**~; asterisk). Expression is maintained in cranial ganglia at late tail bud stages (**D**~**3**~--**D**~**5**~) and becomes apparent in the forebrain and lens (**D**~**3**~; arrowhead). (**E**) During neural plate stages *Pou4f1.2* is expressed in the profundal and trigeminal placodes as well as in a stripe of primary sensory neurons (**E**~**1**~; asterisk; see [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"} for section). In early tail bud stages (**E**~**2**~) expression in the profundal/trigeminal placodes/ganglia and primary neurons is maintained, and expression in the otic and lateral line placodes is strengthened. Expression is maintained in all domains as well as in the cranial ganglia derived from placodes into late tail bud stages when expression becomes up-regulated in the retina (**E**~**3**~; diamond). Dotted line in **E**~**1**~ indicates the level of section shown in [Figure 4--- figure supplement 5](#fig4s5){ref-type="fig"}. (**F**) *Tlx1* is expressed in the presumptive ventral visceral arches at neural plate stages (**F**~**1**~; asterisk). This is maintained into early and late tail bud stages (**F**~**2**~ and **F**~**3**~), which also exhibit prominent expression in the profundal/trigeminal placodes and ganglia and the otic vesicle. Yellow and black arrows mark placodal expression. Bar in **B**~**4**~, **C**~**4 **~and **D**~**4**~: 100 μm (also for **B**~**5**~, **C**~**5**~ and **D**~**5**~, respectively). Abbreviations: pA: anterior placodal region; pAD: anterior lateral line placode; gAD: ganglion of the anterodorsal lateral line nerve; pE: epibranchial placode; pLl: lateral line placodes; L: lens; pL: lens placode; pM: middle lateral line placode; pO: olfactory placode; vOt: otic vesicle; pOt: presumptive otic placode; pPr: profundal placode; pP: posterior placodal region; pPL: posterior lateral line placode; pPrV: profundal/trigeminal placodes; pV: trigeminal placode; gV: ganglion of the trigeminal nerve.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.013](10.7554/eLife.17666.013)10.7554/eLife.17666.014Figure 4---figure supplement 5.Expression of selected targets in pre-placodal ectoderm (PPE) in sections through neural plate stage *Xenopus* embryos.Neural crest and (NC) and neural plate (NP) domains are indicated. (**A**--**D**): *Hes2* (**A**), *Hes8* (**B**), *Hes9* (**C**) and *Pou4f1.2* (**D**) are all expressed in parts of the PPE (for level of sections see [Figure 4 ---figure supplements 3](#fig4s3){ref-type="fig"} and [4](#fig4s4){ref-type="fig"}). While the exact boundaries of NC and NP cannot be determined in these sections, comparisons with sections through embryos stained by double in-situ-hybridisation for the PPE marker *Six1* and the NP marker *Sox3* (**E**) or *Six1* and the NC marker *FoxD3* (**F**) indicate that expression of each of these target genes is largely confined to the PPE although some overlap with the lateral NC region cannot be ruled out (**E** and **F** modified from [@bib86]; [Figure 6](#fig6){ref-type="fig"}). Bar in **A**: 100 μm (also for **B**--**F**).**DOI:** [http://dx.doi.org/10.7554/eLife.17666.014](10.7554/eLife.17666.014)

We found 19/30 (63.3% ) of these transcriptional regulators to be expressed in PPE or placodal derivatives, while 11/30 (*Sox17*, *MyoD1, Sox1, Ets2a, Mafa, Emx1.2, Lhx5, Pou3f2b, Tbx6, Tbx15, Sim1)* were not expressed in either the PPE or any placodal derivatives. However, many of the genes in the latter group were expressed in the adjacent neural folds or other tissues. Thus, it is possible that such genes may be direct targets of Six1 or Eya1 in domains surrounding the PPE, likely to have been included in our screen as a result of non-PPE contamination during dissection. Of the transcriptional regulators identified in our list of well-supported targets and expressed in the PPE or placodal derivatives 79% (15/19) were statistically supported in the analyses of merged datasets ([Table 2](#tbl2){ref-type="table"}). These included genes broadly expressed in cranial ectoderm including the PPE (*Crem, FosB, Znf214, Ripply3*), and genes expressed in the PPE or subdomains of the PPE and subsequently in some placodes (*Hes2, Hes8, Hes9, Mab21l2b, Six1, Six2, Sox2, Sox3, Sox21, Atoh1, Ngn1, Gfi1a, Isl2, Pou4f1.2, Tlx1*) ([Figure 4A--T](#fig4){ref-type="fig"}).

To begin to elucidate the GRN downstream of Six1 and Eya1 we chose ten transcription factors showing expression in posterior placodes (i.e. those derived from the posterior placodal area; the lateral line, otic and epibranchial placodes) for additional functional studies including genes implicated in the maintenance of neuronal progenitors (*Sox2, Sox3, Hes8* and *Hes9*) as well as genes implicated in the regulation of sensory or neuronal differentiation (*Atoh1, Gfi1a, Isl2, Ngn1, Pou4f1.2* and *Tlx1*). Selected genes were independently verified as being direct targets of either Six1 (*Isl2*) or of both Six1 and Eya1 (all other targets; *Sox3* not analysed) in the PPE by qPCR, and the results were broadly consistent with the RNA-Seq data ([Figure 4U and V](#fig4){ref-type="fig"}).

Six1 and Eya1 are required for expression of transcriptional regulators of neurogenesis in the PPE and placodes {#s2-6}
---------------------------------------------------------------------------------------------------------------

To explore whether Six1 or Eya1 were required for the expression of selected target genes, the expression of each target was analysed by in-situ-hybridisation after MO-mediated knockdown of *Six1* or *Eya1*. The efficacy and specificity of both co-injected *Six1*-MOs (*Six1*-MO1 and *Six1*-MO2; [@bib14]) and *Eya1*-MOs (*Eya1*-MO1 and *Eya1*-MO2; [@bib87]) have been previously reported. Compared to injection with a control MO (*Eya1*-mmMO with 5 mismatches relative to Eya1-MO2), knockdown of either *Six1* or *Eya1* significantly reduced the expression of all direct target genes in PPE or placodes, demonstrating that both Six1 and Eya1 are required for their expression ([Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; [Table 3](#tbl3){ref-type="table"}). To control for off-target effects associated with MO use, target gene expression was also analysed after overexpression of a dominant-negative version of *Six1 (Six1-EnR*; [@bib14]). Expression patterns of all target genes were highly similar to those seen after MO-knockdown of either *Six1* or *Eya1*, suggesting that the observed reductions in expression were caused by *Six1* or *Eya1* knockdown as opposed to being an artefact of MO use ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Taken together, these findings show that Six1 and Eya1 are essential direct upstream regulators of multiple genes encoding transcription factors that promote neuro- and sensorigenesis in the PPE and placodes.10.7554/eLife.17666.015Figure 5.Effects of *Eya1* knockdown on target genes.Tail bud (**A**--**G**) and neural plate (**H**--**I**) stage embryos after unilateral injection of *Eya1*-MO1+2. In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**~--**G**~**1**~ show the control (un-injected) side and **A**~**2**~--**G**~**2**~ show the injected side (*lacZ* staining out of frame in most specimens). The injected side is positioned to the right in **H**--**J**, as marked by blue *lacZ* staining. Arrows and arrowheads mark reductions in marker gene expression in placodal and non-placodal derivatives, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.015](10.7554/eLife.17666.015)10.7554/eLife.17666.016Figure 5---figure supplement 1.Effects of Six1 knockdown on target genes.Tail bud stage (**A**--**G**) and neural plate stage (**H**--**J**) embryos after unilateral injection of *Six1*-MO1+2. In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**~--**G**~**1**~ show the control (un-injected) side and **A**~**2**~--**G**~**2**~ show the injected side. The injected side is positioned to the right in **H**--**J**, as marked by blue *lacZ* staining (*lacZ* staining out of frame in some specimens). Arrows mark reductions in marker gene expression in placodal derivatives, and asterisks indicate increased expression.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.016](10.7554/eLife.17666.016)10.7554/eLife.17666.017Figure 5---figure supplement 2.Repression of Six1 target genes by *Six1-EnR* injection.Tail bud stage (**A**--**C**) and neural plate stage (**D**--**I**) embryos after unilateral injection of *Six1-EnR*. In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**--~**C**~**1**~ show the control (un-injected) side and **A**~**2**~--**C**~**2**~ show the injected side. The injected side is positioned to the right in **D**--**I**, as marked by blue *lacZ* staining (*lacZ* staining out of frame in some specimens). Arrows mark reductions in marker gene expression in placodal derivatives, and asterisks indicate increased expression.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.017](10.7554/eLife.17666.017)10.7554/eLife.17666.018Table 3.Changes in marker gene expression in the placodes after injection of various constructs.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.018](10.7554/eLife.17666.018)Injection*Six1*-MO\**Eya1*-MO\*Six1-EnR*Eya1-*mmMOSix1-GR^§^Eya1-GR^§^Phenotype%%%%%%(n)(n)(n)(n)(n)(n)Atoh1Reduced77\*\*90^‡^94102642(26)(20)(18)(21)(19)(12)Increased00003542(26)(20)(18)(21)(17)(12)Gfi1aReduced82^†^67^†^69315736(27)(17)(16)(26)(14)(14)Increased0000743(27)(17)(16)(26)(14)(14)Hes8Reduced74^‡^83^‡^70176057(35)(35)(46)(24)(40)(56)Increased002401529(35)(35)(46)(24)(40)(56)Hes9Reduced73^‡^76^‡^84117529(45)(33)(38)(27)(12)(29)Increased008000(45)(33)(38)(27)(12)(29)Isl2Reduced66^†^100^‡^nd275024(38)(17)nd(22)(18)(17)Increased60nd03141(38)(17)nd(22)(16)(17)Ngn1Reduced65^‡^49^†^84171736(51)(43)(31)(24)(30)(59)Increased016642341(51)(43)(31)(24)(30)(59)Pou4f1.2Reduced67^‡^63^†^71164781(48)(30)(35)(19)(15)(37)Increased0000130(48)(30)(35)(19)(15)(37)Sox2Reduced74^‡^78^‡^8769048(19)(18)(30)(16)(21)(33)Increased0023^\#^0012(19)(18)(30)(16)(21)(33)Sox3Reduced68^‡^54^†^3994940(25)(26)(31)(22)(25)(23)Increased0071^\#^01617(25)(26)(31)(22)(25)(23)Tlx1Reduced84^†^91^‡^10033407(31)(32)(13)(15)(10)(15)Increased60004073(31)(32)(13)(15)(10)(15)[^13][^14][^15][^16][^17][^18][^19]

Six1 and Eya1 affect expression of presumptive direct target genes in complex ways {#s2-7}
----------------------------------------------------------------------------------

To complement the loss-of-function studies, and to examine the spatial distribution of presumptive direct targets of Six1 and Eya1 in gain-of-function experiments, we injected Six1-GR and Eya1-GR individually and, to ensure that overexpression did not affect early embryogenesis, induced their nuclear translocation by adding DEX at neural fold stage (stages 16--18), after PPE commitment ([@bib4]). Surprisingly, although injection of Six1-GR or Eya1-GR resulted in up-regulation of direct targets in a minority of cases ([Table 3](#tbl3){ref-type="table"}; [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}), the dominant observed phenotype was down-regulation of target gene expression in the PPE or placodes ([Table 3](#tbl3){ref-type="table"}; [Figures 8](#fig8){ref-type="fig"} and [9](#fig9){ref-type="fig"}). Considering that here, unlike in the initial RNA-Seq screen and qPCR experiments, CHX was not used to block protein synthesis, these results indicate that Six1 and Eya1 additionally affect expression of many of their direct target genes in indirect and partly opposing ways.10.7554/eLife.17666.019Figure 6.Up-regulation of target gene expression domains after overexpression of Six1.Tail bud stage embryos (**A**--**F**) after unilateral injection of *Six1*-GR and DEX induction at neural plate stage (16--18). In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**~--**F**~**1**~ show the control (un-injected) side and **A**~**2**~--**F**~**2**~ show the injected side. Arrows and arrowheads mark expansions in marker gene expression in placodal and non-placodal derivatives, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.019](10.7554/eLife.17666.019)10.7554/eLife.17666.020Figure 7.Up-regulation of target gene expression domains after overexpression of Eya1.Tail bud stage embryos (**A**--**G**) after unilateral injection of *Eya1*-GR and DEX induction at neural plate stage (16--18). In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**~--**G**~**1**~ show the control (un-injected) side and **A**~**2**~--**G**~**2**~ show the injected side. Arrows and arrowheads mark expansions in marker gene expression in placodal and non-placodal derivatives, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.020](10.7554/eLife.17666.020)10.7554/eLife.17666.021Figure 8.Down-regulation of target gene expression domains after overexpression of Six1.Tail bud stage embryos (**A**--**H**) after unilateral injection of *Six1*-GR and DEX induction at neural plate stage (16--18). In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**--~**H**~**1**~ show the control (un-injected) side and **A**~**2**~--**H**~**2**~ show the injected side. Arrows mark reductions in marker gene expression in placodal derivatives.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.021](10.7554/eLife.17666.021)10.7554/eLife.17666.022Figure 9.Down-regulation of target gene expression domains after overexpression of Eya1.Tail bud stage embryos (**A**--**J**) after unilateral injection of *Eya1*-GR and DEX induction at neural plate stage (16--18). In each case, *lacZ* was co-injected as a lineage tracer and panels **A**~**1**~--**J**~**1**~ show the control (un-injected) side and **A**~**2**~--**J**~**2**~ show the injected side. Arrows mark reductions in marker gene expression in placodal derivatives.**DOI:** [http://dx.doi.org/10.7554/eLife.17666.022](10.7554/eLife.17666.022)

Discussion {#s3}
==========

Overexpression of GR-fusion constructs followed by DEX-induced nuclear translocation in the presence of protein synthesis inhibitors has been previously used successfully to screen for direct target genes of transcription factors or cofactors in *Xenopus* ([@bib49]; [@bib99]; [@bib92]). Here, we combine this approach with high-throughput sequencing of tissue-specific RNA to identify several hundred novel presumptive direct target genes of Six1 and Eya1 in the PPE. We show that this strategy indeed recovers the majority of direct Six1 target genes known from previous studies, indicating its reliability. Our in situ and qPCR analyses of target genes predicted from the RNA-Seq screen also provided independent verification of selected target genes suggesting a low false discovery rate. Moreover, the expression of all genes selected for detailed analysis proved to be dependent on Six1 and Eya1 in the PPE, indicating that many genes our screen predicted as Six1/Eya1 targets are also functionally dependent on these upstream regulators in the PPE. A comparison of our data set with recently identified direct target genes of *sine oculis*, the *Six1* orthologue in the developing eye of *Drosophila* ([@bib45]; [@bib44]) also reveals that homologues to six out of the 12 *sine oculis* target genes identified with high confidence in [@bib44] are differentially expressed in our Six~i~ or Six1+Eya1~i~ (and often also in Eya1~i~) treatment groups, viz. *Six1* and *Six2; Eya4; Shh*; various matrix metalloproteases (e.g. *MMP9); Ets2*; and *Frizzled1* and *Frizzled4*. This suggests that a relatively high proportion of Six1 target genes may be evolutionarily conserved.

Our finding that many of the presumptive direct target genes of Six1 or Eya1 are not up-regulated in the absence of CHX indicates that without blocking protein synthesis it is not possible to reliably identify direct target genes, presumably due to the existence of indirect interactions with such targets. We believe that this is one of the reasons why our findings differ substantially from the study of [@bib108], which analysed differentially expressed genes in *Xenopus* animal cap explants after overexpression of Six1 without first blocking protein synthesis. None of the transcription factors in our prioritised list was identified in the study by [@bib108]; and we found none of the transcription factors differentially expressed in their study. A second likely reason for the discrepancy between the results presented here and in [@bib108] is that, while we specifically analysed PPE tissue (presumably containing tissue-specific cofactors required for the activation or repression of Six1 and Eya1 target genes specific for the developing placodes), they analysed target genes in animal cap tissue, known to be composed of pluripotent cells.

Previous studies have shown that Six1 and Eya1 are essential for both the establishment of the PPE ([@bib14]; [@bib18]), as well as for the subsequent development of placode-derived sense organs ([@bib107]; [@bib52]; [@bib110]; [@bib14]; [@bib112]; [@bib50]; [@bib87]; [@bib3], [@bib2]) but the mechanisms through which they act are poorly understood. The continued expression of both genes in almost all placodes developing from the PPE ([@bib86]), combined with the observed deficiencies in derivatives from most placodes after loss-of-function of either Six1 or Eya1, indicates that they play a role in generic aspects of placode development shared by all placodes. Indeed, our data show that genes revealed as presumptive direct targets of Six1 and Eya1 were highly enriched for GO terms associated with neurogenesis and placode development. Our screen also confirms previous studies suggesting that Six1 and Eya1 synergistically regulate many genes in the PPE, and that the Six1-Eya1 protein complex predominantly acts by activating transcription ([@bib56]; [@bib14]). However, we also find support for independent action of Six1 and Eya1 in the PPE, possibly in conjunction with other interacting partners ([@bib14]; [@bib2]). Surprisingly, we found *Hox* genes to be strongly enriched in the list of target genes activated by Eya1 only. This deserves further study since Eya1 has not previously been recognised as an upstream regulator of *Hox* genes.

It has previously been suggested ([@bib89]) that a generic role of Six1 and Eya1 for all placodes could be implemented in two possible ways: (1) By the direct contribution to the activation of genes regulating developmental processes shared between different placodes such as proliferation, morphogenetic movements and neuronal or sensory cytodifferentiation; or (2) by direct contribution to the activation of genes defining the identity of different individual placodes within the PPE. Our data strongly suggest that Six1 and Eya1 act predominantly in the first rather than in the second mode. A large number of transcription factor encoding genes, including several *Pax, Pitx, ANF* and *FoxI* genes, have been implicated in conferring identity to individual placodes, or groups of placodes, within the PPE (reviewed in [@bib89], [@bib90]; [@bib34]; [@bib83]) however only a few of these genes were recovered as targets of Six1 or Eya1, e.g. *Gbx2* (FC 1.7 in Six1+Eya1~i~) and *FoxI4* (FC 1.09 in Six1~i~). In contrast, we found a large number of genes encoding transcription factors with roles in neuronal/sensory cytodifferentiation but also other proteins with likely roles for the maintenance of proliferating progenitors (e.g. *Cyclin D, RGCC*), the regulation of cell adhesion and morphogenetic movements (e.g. *EDAR, CXCR7, Protocadherin11, RhoV, Claudin3*) and cytodifferentiation (e.g. *Espin, Neurotrophin3*). This suggests that, similar to *Hox* or *Pax* genes, *Six1* and *Eya1* act as both master genes and micro-managers ([@bib5]; [@bib100]; [@bib81]), acting upstream of a GRN co-ordinating cell differentiation in the PPE as well as directly activating terminal differentiation gene batteries.

Considering that Six1 and Eya1 have previously been shown to promote a proliferative progenitor state at high doses but neuronal and sensory differentiation at lower doses ([@bib87]), it is particularly interesting that we identified presumptive direct target genes encoding transcription factors previously implicated in progenitor maintenance (Sox2, Sox3, Hes8, Hes9) and differentiation (Ngn1, Atoh1, POU4f1, Gfi1a, Isl2, Tlx1). Both Hes (Hes8, Hes9) and SoxB1 (Sox2, Sox3) proteins are known to keep progenitor cells in an undifferentiated state, and must be down-regulated for neuronal differentiation to proceed. While Sox2 and Sox3 play multiple roles including activity as pioneer factors, which open up chromatin for transcription ([@bib15]; [@bib31]; [@bib79]; [@bib8]), Hes proteins generally repress neuronal/sensory determination genes such as *Ngn1* or *Atoh1* as effectors of Notch signalling ([@bib47]; [@bib96]; [@bib1]). Conversely, Ngn1 and Atoh1 are known to act as proneural factors that initiate differentiation of sensory neurons and hair cells, respectively ([@bib61], [@bib60]; [@bib9]; [@bib66]), whereas POU4f1 (previously known as Brn3a), Gfi1a, Isl2 and Tlx1 act further downstream in differentiation of sensory neurons ([@bib76]; [@bib103]; [@bib17]; [@bib27]; [@bib54]; [@bib26]), and Gfi1a and the related POU domain factor POU4f3 (or Brn3c) are required for hair cell maintenance and survival ([@bib104]; [@bib103]). Our findings strongly indicate that Six1 and Eya1 directly promote multiple steps during sensory and neuronal development, and act to drive both progenitor maintenance and neuronal differentiation programmes in placodes (summarised in [Figure 10](#fig10){ref-type="fig"}), although further functional studies are needed to clarify the mechanism allowing Six1 and Eya1 to maintain the balance between activation of progenitor and differentiation genes. Additionally, direct binding of Six1 to regulatory regions of targets identified in this study should be confirmed by methods such as ChIP-Seq.10.7554/eLife.17666.023Figure 10.Network summary for Six1/Eya1-activated gene regulation in the PPE.Six1/Eya1 act to promote neuronal differentiation, by activation of pro-neural genes (*Ngn1, Atoh1*), as well as progenitor state maintenance, by activation of genes such as *SoxB1* and *Hes* genes. Arrows indicate direct (solid line) and indirect (dotted line) activation; barred lines show direct (solid line) and indirect (dotted line) repression. Evidence for interactions: Six1 positively autoregulates ([@bib85]); Six1/Eya1 directly activate Sox2, Sox3, Hes8, Hes9, Ngn1, Atoh1, Isl2, Pou4f1.2, Tlx1 and Gfi1a (this study); Sox2 synergises with Six1/Eya1 ([@bib3], [@bib2]); Sox2 directly activates Atoh1 ([@bib2]) and Ngn1 ([@bib19]); Atoh1 and Ngn1 indirectly repress each other ([@bib30]); Ngn1 indirectly represses Sox2 ([@bib28]); Ngn1 directly activates NeuroD1 ([@bib92]); Atoh1 positively autoregulates ([@bib36]); Atoh1 indirectly represses Sox2 ([@bib68]) and activates Gfi1 ([@bib103]); NeuroD1 directly activates Pou4f1.2 ([@bib42]) and Isl1 ([@bib55]); Pou4f1.2 directly activates Gfi1 ([@bib37]) and indirectly activates Tlx1 ([@bib42]).**DOI:** [http://dx.doi.org/10.7554/eLife.17666.023](10.7554/eLife.17666.023)

The analysis of Six1 and Eya1 presumptive direct target genes presented here establishes a GRN regulating the development of cranial vertebrate sensory organs and neurons from the PPE ([Figure 10](#fig10){ref-type="fig"}), and identifies a large number of novel putative direct target genes encoding a diverse array of proteins. Among these are many promising candidates potentially involved in mediating the effects of Six1 or Eya1 on proliferation, morphogenesis and cytodifferentiation in developing placodes. This makes our data an invaluable repository of information for designing further functional studies on early sensory development in vertebrates. Finally, while our study focussed on the role of Six1 and Eya1 during sensory development, cell proliferation, morphogenesis and cytodifferentiation are also known to be affected in human patients in which Six1 and Eya1 are dysregulated, leading to sensory deficits after *Six1* or *Eya1* loss of function mutations ([@bib48]) or enhanced tumour progression after *Six1* or *Eya1* up-regulation ([@bib11]; [@bib59]). This suggests that many target genes identified in our study may also be misregulated in these diseases, potentially opening up exciting new avenues for therapeutic intervention.

Materials and methods {#s4}
=====================

Expression constructs and morpholinos {#s4-1}
-------------------------------------

Capped RNAs of *Xenopus Six1-GR, Eya1-GR* and *Six1-EnR* were made by in vitro transcription using the mMessage mMachine SP6 kit (Ambion, Austin, Texas) from the following templates: pCS2^+^-GR-myc-Six1, pCS2^+^-GR-myc-Eya1α ([@bib87]) and pCS2-EnR-Six1 ([@bib14]).

Translation blocking morpholinos (MO) for Six1 (*Six1*-MO1: 5'-GGAAGGCAGCATAGACATGGCTCAG-3'; *Six1*-MO2: 5'-CGCACACGCAAACACATACACGGG-3') and Eya1 (*Eya1*-MO1: 5'-TACTATGTGGACTGGTTAGATCCTG-3'; *Eya1*-MO2: 5'-ATATTTGTTCTGTCAGTGGCAAGTC-3') were previously described ([@bib14]; [@bib87]). An *Eya1*-MO carrying 5 mismatches was used as a control (*Eya1*-mmMO; mismatches shown in lower case: 5'-ATtTTaGTTCTGaCAGTGGgAAcTC-3').

Microinjection {#s4-2}
--------------

*Six1-GR* (500 pg), *Eya1-GR,* (500 pg), *Six1-EnR* (100 pg) mRNAs and *Six1*-MO1+2 (2 ng), *Eya1*-MO1+2 (2 ng), and *Eya1*-mismatch-MO (2 ng) were freshly prepared before each injection. *lacZ* (250 pg) or *myc-GFP* (125 pg) mRNAs were co-injected to mark the injected side. Embryos of *Xenopus laevis* were obtained by in vitro fertilisation, staged according to ([@bib70]) and injected unilaterally into two-cell blastomeres according to standard procedures ([@bib94]). *Six1-EnR* was injected at the four-cell stage into single blastomeres that give rise to the dorsal ectoderm as previously described ([@bib14]).

Conditional overexpression of GR-fusion constructs and isolation of placodal RNA {#s4-3}
--------------------------------------------------------------------------------

To obtain RNA for RNA-Seq or qPCR, both blastomeres of two-cell stage embryos were injected with either 1) *Six1-GR* (500 pg) + *myc-GFP* (125 pg), 2) *Eya1-GR* (500 pg) + *myc-GFP* (125 pg), or 3) *Six1-GR* (500 pg) + *Eya1-GR* (500 pg) + *myc-GFP* (125 pg). Each of these treatment groups was allowed to develop to early neural plate stage before being sorted under a fluorescent microscope. The lateral part of the preplacodal region (LPR of [@bib4]) was explanted from GFP positive embryos (\~100 per biological replicate) in 1 × MBSH ([@bib94]) supplemented with 2 mM CaCl~2~, 25 mg/l gentamycine (Sigma, St Louis, Missouri), 400 mg/l penicillin (Sigma), and 400 mg/l streptomycin sulphate (Sigma). Explants were pre-treated with 0.1 × modified Barth's solution (MBS; [@bib94]) with cycloheximide (CHX; final concentration 10 μg/ml) for 30 min at 25°C. After pre-treatment, 50% of the explants were transferred to 0.1 × MBS with CHX + dexamethasone (DEX; final concentration 10 μM) and incubated for 2 hr 30 at 25°C ([Figure 1](#fig1){ref-type="fig"}) when control embryos had reached stage 20. Explants were immediately homogenised in Trizol (Invitrogen, Carlsbad, California) and total RNAs extracted. Isolated RNA was quality assayed in an Agilent 2100 Bioanalyzer and all samples used for sequencing had an RIN \>7.0.

RNA-sequencing, mapping and annotation {#s4-4}
--------------------------------------

Libraries were prepared from 1 mg total RNAs and subjected to deep sequencing with Illumina Hi-Seq1000 at the EMBL Genecore facility. Paired-end (100 bp) sequence reads were quality-filtered using Trimmomatic ([@bib12]), and mapped to the *Xenopus laevis* genome (XL7.0) with Bowtie2 (version 2.2.5; [@bib53]) and Tophat2; (version 2.0.13; [@bib46]). An average of 65 million reads (\~80% of quality filtered reads) were mapped with 90% of reads properly paired in sequencing across treatment groups. Transcript models were assembled using Cufflinks2 (version 2.1.1; [@bib101]), and differential expression was determined using Cuffdiff2 (version 2.1.1; [@bib101]). Gene models were annotated against a combined *Xenopus* mRNA database (*X. laevis*: ftp://ftp.xenbase.org/pub/Genomics/Sequences/xlaevisMRNA.fasta; *X. tropicalis*: ftp://ftp.xenbase.org/pub/Genomics/Sequences/xtropMRNA.fasta) using blastn with an e-value cut-off of 1E-5. Using this approach we were able to annotate an average of 80% of mapped reads.

Differential expression analysis for individual treatment groups {#s4-5}
----------------------------------------------------------------

Initially, two samples of CHX- and CHX+DEX-treated explants were independently collected, sequenced and mapped for each treatment group (injection of Six1-GR, Eya1-GR or Six1-GR+Eya1-GR), and were specified as two biological replicates in Cuffdiff. To preclude the inclusion of genes affected by DEX treatment alone, we also analysed explants taken from un-injected embryos and treated as above (CHX vs. CHX+DEX). Two biological replicates of this control treatment group were included in sequencing. Presumptive direct targets of Six1, Eya1 or Six1+Eya1 were determined by comparing Six1-GR, Eya1-GR or Six1-GR+Eya1-GR-injected embryos treated with CHX (as controls) against CHX+DEX-treated samples. Genes were considered to be differentially expressed if (1) the FPKM ([F]{.ul}ragments [P]{.ul}er [K]{.ul}ilobase of exon per [M]{.ul}illion fragments mapped) for that gene was \>1 in the CHX+DEX treatment group, (2) the gene was at least two-fold up-/down-regulated after CHX+DEX treatment compared to CHX treatment, (3) there was at least a two-fold difference between the control (un-injected) and experimental (injected with either Six1-GR, Eya1-GR or Six1-GR+Eya1-GR) fold change (FC) values in response to DEX treatment. The Pearson correlation was high for each of the treatment groups (\>0.9 for all pairwise comparisons), indicating the similarity of expression profiles between independently treated samples.

Re-analysis of differential expression for combined treatment groups {#s4-6}
--------------------------------------------------------------------

As a second approach to finding genes that showed differential expression in response to DEX treatment, RNA-Seq data of several treatment groups were merged to add statistical power to the analysis. In one analysis, all replicates from our three different treatment groups were considered as equivalent to focus on genes with similar differential expression profiles across all treatment groups (comprising the Six1+Eya1~m~ dataset with six replicates). In another analysis, all treatment groups involving *Six1* overexpression (i.e. injection of Six1-GR alone or Six1-GR+Eya1-GR: Six1~m~ with 4 replicates) were treated as equivalent as were all treatment groups involving *Eya1* overexpression (Eya1-GR, Six1-GR+Eya1-GR: Eya1~m~ with 4 replicates). This allowed us to focus on genes whose activation was limited by either Six1 or Eya1 levels. We considered a gene to be significantly differentially expressed if it passed Cuffdiff's statistical test (q \< 0.05) in addition to meeting the criteria outlined above.

Gene set enrichment analysis (GSEA) and Gene Ontology {#s4-7}
-----------------------------------------------------

*Xenopus* annotations were converted to their human orthologs from the Human Uniprot database, and functionally annotated using the online tools 'PantherDB' ([@bib65]; <http://pantherdb.org>) and 'DAVID' ([@bib40]; <https://david.ncifcrf.gov>). For GSEA of placodal transcriptomes after injection of Six1 and/or Eya1, the placodal transcriptome of un-injected, CHX treated placodal explants was specified as a background set, whereas GSEA of the transcriptome of untreated explants was conducted using the default \'human dataset\' in DAVID as background. The [e]{.ul}nrichment score (E) for each group is reported as the geometric mean of the EASE scores (a modified Fisher's exact score) that are associated with the enriched annotation terms belonging to that group ([@bib39]).

cDNA synthesis and qPCR {#s4-8}
-----------------------

RNA was extracted from explants after CHX or CHX+DEX treatment as detailed above. cDNA was synthesised using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany), using 500 ng total RNA according to the manufacturer's protocol. qPCR was performed using Taqman reagents on a StepOne Plus machine (Applied Biosystems, Foster City, California), using *Smn2* as a reference ([@bib25]; [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). qPCR was performed in triplicate and the entire experiment was repeated three times from independently prepared RNA. Relative Quantification (RQ) values and log~2~ fold change (FC) were averaged across biological replicates.

Subcloning and gene synthesis {#s4-9}
-----------------------------

The full coding region of *Hes8, Crem, FosB, Tbx15, Atoh1* and *Isl2* was synthesised from transcript models from RNA-Seq data (KT722743; KT722744; KT722745; KT722746; KT722747; KT722748) by Genescript into the cloning vector pUC57 and subsequently sub-cloned into the expression vector pCS2^+^ using the following restriction sites: *Hes8* and *Crem:* ClaI/EcoRI; *Atoh1:* XbaI; *Tbx15* and *FosB:* BamHI/EcoRI; *Isl2:* EcoRI/StuI. Primers with added ClaI and EcoRI sites (to the forward and reverse primers, respectively) were designed ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}) to amplify the entire coding region of *Tbx6*, which was then subcloned into pCS2^+^ between the ClaI/EcoRI sites. *Znf214, Mab21l2-b* and *Pou3f2b* were ordered (pCMV-SPORT6, Fisher Scientific, Waltham, Massachusetts; Clone IDS: 5512398, 5515985 and 4203106).

*Hes9* (pCR4-TOPO) was ordered from Source Bioscience (Clone accession: BC169570) and was subcloned into the EcoRI site of pCS2^+^.

In-situ-hybridisation {#s4-10}
---------------------

Embryos injected with *myc-GFP* were sorted under a fluorescent microscope and fixed using a standard protocol ([@bib94]). *LacZ*-injected embryos were fixed and then stained with X-gal solution to reveal lacZ. Wholemount in-situ-hybridisation was carried out under high stringency conditions at 60°C as previously described ([@bib35]) using digoxigenin-labelled antisense probes. Probes for *Six1* ([@bib75]), *N-tubulin* ([@bib74] *Sox2* ([@bib24]), *Sox3* ([@bib77]), *Ripply3* ([@bib43]), *Hes2* ([@bib97]), *Sim1* ([@bib63]), *Gbx2* ([@bib102]), *Lhx5* ([@bib7]), *Sox21* ([@bib22]), *Emx1.2* ([@bib32]), *Pou4f1.2* ([@bib42]), and *Tlx1* ([@bib76]) were synthesised as previously described. Primers were designed with promoter sites added (forward, T7; reverse, SP6) for *Hes8, Hes9, Gfi1a, Tbx15, Ngn1, Pou4f1.2* and *Isl2* and were used to amplify a \~800 bp fragment from plasmid DNA ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}) which was then used as a template for probe synthesis using T7 RNA polymerase to make an antisense probe. pCMV-SPORT6 with *Znf214, Mab21l2-b* and *Pou3f2b* were linearised with SalI and antisense probes synthesised with T7. pCS2^+^ vectors containing *Tbx6, FosB* and *Crem* were linearised with BamHI and transcribed with T7. pCS2^+^ with *Atoh1* was linearised with NotI and transcribed with SP6.

Vibratome sections and immunohistochemistry {#s4-11}
-------------------------------------------

In order to analyse the distribution of gene expression domains in finer detail, serial 40--50 μM vibratome sections were cut from selected embryos after wholemount in-situ hybridisation. Where staining with X-gal was insufficient to reveal the injected site, lacZ distribution was revealed immunohistochemically using a polyclonal rabbit anti-LacZ (MP Biomedicals Cappel, Santa Ana, California; Cat.: 55976; 1:1000) and an Alexa594-conjugated anti-rabbit antibody (1:1000).

Availability of data and material {#s4-12}
---------------------------------

All sequencing data have been deposited in the NCBI BioProject database under BioProject PRJNA317049. All scripts used in analysis are available at [https://github.com/nriddiford/Six1-Eya1-RNA-Seq.git.](https://github.com/nriddiford/Six1-Eya1-RNA-Seq.git)
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###### Top 1000 expressed genes (by FPKM) in the placodal transcriptome.

**DOI:** [http://dx.doi.org/10.7554/eLife.17666.024](10.7554/eLife.17666.024)
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###### Tables of differentially expressed genes after overexpression of Six1-GR, Eya1-GR or Six1-GR+Eya1-GR: Individual treatment groups. 

Table 1: Genes with at least two-fold up-regulation after injection of Six1-GR and treatment with CHX + DEX. Table 2: Genes with at least two-fold up-regulation after injection of Eya1-GR and treatment with CHX + DEX. Table 3: Genes with at least two-fold up-regulation after injection of Six1-GR+Eya1-GR and treatment with CHX + DEX. Table 4: Genes with at least two-fold down-regulation after injection of Six1-GR and treatment with CHX + DEX. Table 5: Genes with at least two-fold down-regulation after injection of Eya1-GR and treatment with CHX + DEX. Table 6: Genes with at least two-fold down-regulation after injection of Six1-GR+Eya1-GR and treatment with CHX + DEX.

**DOI:** [http://dx.doi.org/10.7554/eLife.17666.025](10.7554/eLife.17666.025)
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###### Tables of differentially expressed genes after overexpression of Six1-GR, Eya1-GR or Six1-GR+Eya1-GR: Merged treatment groups.

Table 1: Genes with at least two-fold up-regulation after injection of Six1-GR or Six1-GR+Eya1-GR and treatment with CHX + DEX. Table 2: Genes with at least two-fold up-regulation after injection of Eya1-GR or Six1-GR+Eya1-GR and treatment with CHX + DEX. Table 3: Genes with at least two-fold up-regulation after injection of Six1-GR or Eya1-GR or Six1-GR+Eya1-GR and treatment with CHX + DEX. Table 4: Genes with at least two-fold down-regulation after injection of Six1-GR or Six1-GR+Eya1-GR and treatment with CHX + DEX. Table 5: Genes with at least two-fold down-regulation after injection of Eya1-GR or Six1-GR+Eya1-GR and treatment with CHX + DEX. Table 6: Genes with at least two-fold down-regulation after injection of Six1-GR or Eya1-GR or Six1-GR+Eya1-GR and treatment with CHX + DEX.

**DOI:** [http://dx.doi.org/10.7554/eLife.17666.026](10.7554/eLife.17666.026)
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###### Primer sequences with modifications.

**DOI:** [http://dx.doi.org/10.7554/eLife.17666.027](10.7554/eLife.17666.027)

Major datasets {#s7}
--------------

The following dataset was generated:

Riddiford N,Schlosser G,2016,PRJNA317049,<http://www.ncbi.nlm.nih.gov/bioproject?LinkName=biosample_bioproject&from_uid=4640079>,Publicly available at the NCBI BioProject database (accession no: PRJNA317049)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Dissecting the pre-placodal transcriptome to reveal direct targets of Six1 and Eya1 in cranial placodes\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by K VijayRaghavan as the Senior Editor and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Sally Moody (Reviewer \#1) and Jean-Pierre Saint-Jennet (Reviewer \#2)

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting transcriptomic analysis of the direct targets of Six1 and Eya1 in the pre-placodal ectoderm (PPE). This is a very important analysis because both genes are critical for the development of cranial sensory organs and they are mutated in a human developmental defect, branchio-oto-renal syndrome. Although the role of Six1 and Eya1 in cranial placode development has been established for over 15 years, their direct transcriptional targets have not yet been analyzed in a comprehensive manner in a vertebrate model. This study uses techniques that have been very successful in *Xenopus* to detect direct transcriptional targets by expressing hormone inducible versions of Six1 and Eya1 in the presence of protein synthesis inhibitors. The authors have meticulously dissected out the precursor cells of the cranial placodes, the PPE, which provides important tissue specificity to the results. In addition, they make important comparisons between Six1 only, Eya1 only and Six1 + Eya1 targets. This is important because the literature shows in both fly and vertebrates that both proteins have alternate binding partners that can influence target gene specificity. This work is carefully carried out, includes appropriate controls and provides important new information for the community.

Some of the strengths/novelty of this manuscript are:

1\) A comparison to a neural crest data set (Simoes-Costs 2014), which is interesting because it is a related but distinct tissue.

2\) Inclusion of a Chx-treated only sample, which would identify genes that are expressed when repression is relieved.

3\) qPCR validation of RNA-seq and excellent controls for the MO-knockdown experiments.

4\) Confirmation of known Six1 targets based on the literature

5\) Implication that Eya1 may not always act as a co-activator with Six1; this could be very important and explain some unexplained observations in the literature.

6\) Solid evidence that Six1 works with other co-factors and Eya1 works with other partners in PPE development.

7\) Potential role of Eya1 in regulating Hox genes

8\) Comparison of the RNA-seq data to previously published microarray analysis.

Essential revisions: (These are all straightforward)

Our main concern with the manuscript is whether the authors have truly identified direct targets of Six1 and Eya1, as the title suggest. We are not sure based on the experimental approach used here, that the authors can make this claim. Direct targets cannot be defined just based on cycloheximide treatment experiments, especially since there is no indication of the efficiency of the treatment at blocking protein synthesis in this assay. Moreover, cycloheximide has been shown to alter gene expression on its own (see Sinner et al., 2004) -- though the authors appear to have the appropriate controls. The identification and validation of Six1 binding sites in the regulatory regions of these targets would make for a much stronger case in favor of genuine direct targets. Until this is done, we suggest that the authors revise the wording throughout the manuscript by using terms such as \"potential direct targets\" or \"presumptive direct targets\". While it is very probable their list of genes contain direct targets, it seems unlikely that Six1 and Eya1 directly regulate the expression of several hundred genes in the PPE as stated at the beginning of the Discussion.

As a way of validating the approach and the quality of the data, the authors searched for established targets of Six1 in their data sets, however some of these genes (*Sox2* and Atoh1) are also upregulated in the Eya1 samples ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). What does it say about these targets and the quality of the data if they can be regulated independently of Six1? This should be discussed.

While this group has the demonstrated expertise to identify the various placodal domains at different stages of *Xenopus* development, it would be useful in some instances to confirm the placodal expression domain of these targets using well-characterized genes expressed in the same domain or in adjacent tissues, either using double ISH or single ISH in stage-matched embryos. For example, the expression pattern of Hes2 at the neurula stage appears to be largely confined to the neural crest territory, but [Figure 4F](#fig4){ref-type="fig"} indicate that it is expressed in the posterior placodal region.

10.7554/eLife.17666.031

Author response

*Essential revisions: (These are all straightforward)*

*Our main concern with the manuscript is whether the authors have truly identified direct targets of Six1 and Eya1, as the title suggest. We are not sure based on the experimental approach used here, that the authors can make this claim. Direct targets cannot be defined just based on cycloheximide treatment experiments, especially since there is no indication of the efficiency of the treatment at blocking protein synthesis in this assay. Moreover, cycloheximide has been shown to alter gene expression on its own (see Sinner et al., 2004) -- though the authors appear to have the appropriate controls. The identification and validation of Six1 binding sites in the regulatory regions of these targets would make for a much stronger case in favor of genuine direct targets. Until this is done, we suggest that the authors revise the wording throughout the manuscript by using terms such as \"potential direct targets\" or \"presumptive direct targets\". While it is very probable their list of genes contain direct targets, it seems unlikely that Six1 and Eya1 directly regulate the expression of several hundred genes in the PPE as stated at the beginning of the Discussion.*

We have now worded the manuscript more carefully and use "presumptive direct targets" throughout.

*As a way of validating the approach and the quality of the data, the authors searched for established targets of Six1 in their data sets, however some of these genes (Sox2 and Atoh1) are also upregulated in the Eya1 samples ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). What does it say about these targets and the quality of the data if they can be regulated independently of Six1? This should be discussed.*

Since many Six1 target genes are coregulated by Eya1 this is actually to be expected. To clarify this issue we have now added the following sentences to the relevant section: "Moreover, *Atoh1, Sox2* and *MyoD1* were found both in our Six1+Eya1~i~ and Eya1~i~ datasets as expected based on the known coregulation of these Six1 target genes by Eya1 (Grifone et al., 2007; Ahmed et al., 2012 a; Schlosser et al., 2008). We suggest that overexpression of Eya1 alone may upregulate such genes in those parts of the ectoderm where Six1 is already expressed at high levels but Eya1 at relatively low levels in vivo."

*While this group has the demonstrated expertise to identify the various placodal domains at different stages of Xenopus development, it would be useful in some instances to confirm the placodal expression domain of these targets using well-characterized genes expressed in the same domain or in adjacent tissues, either using double ISH or single ISH in stage-matched embryos. For example, the expression pattern of Hes2 at the neurula stage appears to be largely confined to the neural crest territory, but [Figure 4F](#fig4){ref-type="fig"} indicate that it is expressed in the posterior placodal region.*

Following the reviewer's suggestions, we now have added a new figure ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}) showing cross-sections through neural plate stage embryos expressing Hes2, Hes8, Hes9 and Pou4f1.2 in comparison to cross-sections from embryos after double in situ for Six1/Sox3 and Six1/FoxD3 (the latter taken from the previous study of Schlosser and Ahrens, 2004). This shows that Hes2 as well as the other genes are predominantly expressed in the PPE and not the neural crest at neural plate stages (even though some overlap with the lateral part of the neural crest cannot be ruled out based on our data). We also have added images of Six1 expression in stage-matched embryos as an additional row to [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}-4 to facilitate comparison of expression domains.

[^1]: \* Genes are ranked by FC value, using the highest FC in each of the three treatment groups. Genes included must have FC ≥ 1 in at least two out of the three treatment groups as well as showing at least a two-fold difference in FC to the un-injected control (not shown). Corresponding values ≥0.5 are shown for all treatments.

[^2]: ^†^ Log~2~ Fold change values after Six1-GR overexpression.

[^3]: ^‡^ Log~2~ Fold change values after Eya1-GR overexpression.

[^4]: ^§^ Log~2~ Fold change values after Six1-GR+Eya1-GR overexpression.

[^5]: ^\#^ Denotes transcription factors with at least a two-fold change in at least two treatment groups selected for further analysis.

[^6]: \*Log~2~ fold change values after *Six1* overexpression (Six1~i~).

[^7]: ^†^ Log~2~ fold change values after *Eya1* overexpression (Eya1~i~).

[^8]: ^‡^ Log~2~ fold change values after *Six1+Eya1* overexpression (Six1+ Eya1~i~).

[^9]: ^§^ Log~2~ fold change values after overexpression of *Six1* or *Six1+Eya1* (Six1~m~).

[^10]: ^\#^ Log~2~ fold change values after overexpression of *Eya1* or *Six1+Eya1* (Eya1~m~).

[^11]: ^¶^ Log~2~ fold change values after overexpression of *Six1* or *Eya1* or *Six1+Eya1* (Six1+Eya1~m~).

[^12]: \*\* Denotes statistically supported data (q \< 0.05).

[^13]: \* Significant differences (Fisher's exact test);.

[^14]: ^†^ p\<0.05,.

[^15]: ^‡^ p\<0.001) to *Eya1-*mmMO injections are indicated.

[^16]: ^§^ Dexamethasone treatment from stages 16--18 on.

[^17]: ^\#^ Expression ectopic in epidermis.

[^18]: n: Number of embryos analysed at both neural plate (stage 14--16) and tail bud (stage 21--26) stage.

[^19]: nd: Not determined.
